



| | |
|------------------|---|
| Title | Molecular epidemiological study of multidrug-resistant Mycobacterium tuberculosis in Lusaka, Zambia |
| Author(s) | Chizimu, Yamweka Joseph |
| Citation | 北海道大学. 博士(感染症学) 甲第15043号 |
| Issue Date | 2022-03-24 |
| DOI | 10.14943/doctoral.k15043 |
| Doc URL | http://hdl.handle.net/2115/86060 |
| Type | theses (doctoral) |
| File Information | CHIZIMU_Yamweka_Joseph.pdf |



[Instructions for use](#)

**Molecular epidemiological study of multidrug-resistant
Mycobacterium tuberculosis in Lusaka, Zambia**

(ザンビア、ルサカ市における多剤耐性結核の分子疫学的研究)

Chizimu Yamweka Joseph

**Division of Bioresources
International Institute for Zoonosis Control
Hokkaido University**

Table of Contents

| | |
|---|----|
| <i>LIST OF FIGURES</i> | 4 |
| <i>LIST OF TABLES</i> | 6 |
| <i>ABBREVIATIONS</i> | 7 |
| <i>NOTES</i> | 8 |
| <i>PREFACE</i> | 9 |
| | |
| <i>CHAPTER 1</i> | 30 |
| Introduction..... | 30 |
| Materials and methods..... | 31 |
| Sample collection, processing, DNA extraction..... | 31 |
| Drug-resistance associated gene sequencing..... | 31 |
| Spoligotyping..... | 31 |
| MIRU-VNTR typing..... | 32 |
| Phylogenetic analysis..... | 33 |
| Comparison of CAS1-Kili and LAM1 strains..... | 33 |
| Detection of RD-Rio sub-lineage strains..... | 33 |
| Ethical approval..... | 34 |
| Results..... | 35 |
| Demographic profile..... | 35 |
| Drug-resistance associated gene sequencing..... | 35 |
| Spoligotyping..... | 35 |
| MIRU-VNTR genotyping and phylogeny..... | 35 |
| Comparison of CAS1-Kili and LAM1 strains..... | 36 |
| Detection of RD-Rio sub-lineage strains..... | 36 |
| Discussion..... | 37 |
| Conclusion..... | 41 |
| Summary..... | 42 |
| | |
| <i>CHAPTER 2</i> | 53 |
| Introduction..... | 53 |
| Materials and Methods..... | 55 |
| Study samples..... | 55 |
| Culturing and drug susceptibility testing..... | 55 |
| DNA extraction and genotyping..... | 55 |
| Whole-genome sequencing analysis..... | 55 |
| Phylogenetic assessment of global sub-lineage CAS1-Kili (L3.1.1)..... | 56 |
| Results..... | 57 |
| Cluster analysis..... | 57 |
| Resistance patterns and Phylogeny..... | 57 |
| Phylogenetic assessment of global sub-lineage CAS1-Kili (L3.1.1)..... | 57 |
| Discussion..... | 59 |
| Conclusions..... | 62 |
| Summary..... | 63 |
| | |
| <i>CONCLUSION</i> | 82 |

ACKNOWLEDGMENTS.....84
REFERENCES.....85

LIST OF FIGURES

- Figure 1. Figure showing Zambia among the three global lists for high-burden countries for TB, HIV-associated TB and MDR/RR-TB adapted from WHO 2021b. Each of the three lists is represented by a specific color; blue for MDR/RR-TB, red for TB and orange for TB/HIV. Some countries including Zambia, are in more than one list as shown by the overlapping areas.20
- Figure 2. WHO TB incidence rate estimates for the year 2020 adapted from WHO 2021b. The map was shaded according to the incidence per 100, 000 population per year as indicated in the legend.21
- Figure 3. Phylogenetic tree showing the seven human and animal adapted lineages rooted to *M. canetti* adapted from Coscolla 2017. (b) Global map showing the distribution of four of the seven lineages (b) and (c) sub-lineages. (Data adapted from Chihota et al. 2018 and SITVIT2 WEB Database available on <http://www.pasteur-guadeloupe.fr:8081/SITVIT2/index.jsp>). Some lineages are widely distributed while others are restricted to certain geographic regions.22
- Figure 4. Mycobacterium cell wall structure adapted from Kaiser 2019.24
- Figure 5. Diagram illustration the genotyping methods utilized in this dissertation. (a). Spoligotyping (Kamerbeek et al. 1997) (b). MIRU-VNTR (Supply et al. 2006) (c). Whole genome sequencing adapted from Disease Profiling Project 2018.25
- Figure 6. Zambia tuberculosis incidence and mortality estimates per 100,000 population for the period 2000 to 2020 (WHO 2021b).28
- Figure 7. Estimated TB cases with MDR/RR-TB among the new and previously treated cases (WHO 2016, 2017, 2018, 2019a).29
- Figure 8. Map showing regions (in green) referring patients and samples to the University Teaching Hospital in Lusaka, Zambia. The regions (yellow) refer patients to Ndola Central Hospital.47
- Figure 9. Dendrogram based on 24 loci MIRU-VNTR and spoligotyping patterns constructed by (UPGMA). pDST and gDST = phenotypic and genotypic drug susceptibility.48
- Figure 10. Minimum spanning tree constructed using 24-loci MIRU-VNTR profile. Strains with single-locus differences were grouped in 7 clonal complexes. Line thickness indicates loci differences. The variations in size and partitions in each node correspond to the number of strains. Figures on the nodes are SIT numbers.49
- Figure 11. Figure showing the distribution of MDR *M. tuberculosis* strains according to sub-lineages in Zambia and its neighboring countries. The countries in white implies that the data was not captured or was not adequate.50
- Figure 12. Dendrogram showing the relationship of the Zambian strains (SIT20/LAM1 and SIT21/CAS1-Kili) with African strains from SITVIT 2 database, Mbugi et al. 2015 and Perdigão et al. 2017 based on standard 12 loci MIRU-VNTR. The

| | |
|---|----|
| strains had same spoligotyping octal patterns; 703377400001771 for SIT21/CAS1-Kili and 677777607760771 for SIT20/LAM1. | 51 |
| Figure 13. Dendrogram showing 24-MIRU-VNTR and spoligotyping patterns. The order of 24-MIRU-VNTR from left to right: MIRU02, MIRU04, MIRU10, MIRU16, MIRU20, MIRU23, MIRU24, MIRU26, MIRU27, MIRU31, MIRU39, MIRU40, ETR-A, ETR-B, ETR-C, ETR-F, Mtub04, Mtub21, Mtub30, Mtub39, QUB11a, QUB11b, QUB26, and QUB4156. RD represents RD-Rio sublineage. | 52 |
| Figure 14. Distribution of SIT21/CAS1-Kili strains by country. Data obtained from SITVIT2 MTBC Database (Demay et al. 2012). | 64 |
| Figure 15. Phylogenetic tree illustrating the relations of the studied SIT21/CAS1-Kili strains. Drug-resistance-associated mutations of each strain are represented by different shapes on the branches and highlighted as indicated by the legend. Fs in the legend stand for frameshift. A, is for phenotypic drug susceptibility patterns. Black and white circles represent results of drug-resistant and susceptible phenotypes, respectively. B, Represents drug-resistant-associated mutations. Black and white squares indicate the presence and absence of drug-resistance-associated mutations to a particular drug, respectively. CTK in the district column stands for a district Chikankata. An 'S' letter before each ID number stands for strain. In the legend, RIF, INH, STR, EMB and PZA stand for rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide, respectively. | 65 |
| Figure 16. Nucleotide changes in drug resistance associated genes and number of strains having the same nucleotide change among the 13 SIT21/CAS1-Kili strains. The strain IDs are arranged in relation to Figure 15 (Starting from the top). Fs in the figure represents frameshift. | 66 |
| Figure 17. (a). Phylogenetic tree for global L3.1.1 strains. The countries are represented by small circles on the tips of the tree and colored as shown in the legend. The inner (R) and outer circles (C) were colored according to the drug resistance patterns and regions of strain isolation (as continents), respectively. (b). Enlargement of the clade containing the Zambian strains. | 67 |
| Figure 18. Comparison of median SNP distances of global representative L3.1.1 strains by country to Zambian strains. The differences in median SNP distance were significant ($p < 0.000$). Only countries with more than 10 strains were considered. | 68 |
| Figure 19. Phylogenetic tree with detailed drug resistant mutations for each global L3.1.1 strain. R = rifampicin, I = isoniazid, P = pyrazinamide, E = ethambutol, S = streptomycin, A = drug resistance pattern, C = continent. | 70 |
| Figure 20. Map showing the residence districts of the 12 patients highlighted in different colors. Seven patients were from Lusaka, and one from Chikankata. Monze and Kabwe had two patients each. | 71 |

LIST OF TABLES

| | |
|--|----|
| Table 1. Advantages and disadvantages of molecular genotyping methods | 18 |
| Table 2. Table showing spoligotype-based diversity of the 85 strains under the study | 43 |
| Table 3. MIRU-VNTR discriminatory powers for 9, 15, and 24 loci on predominant clades in our study | 44 |
| Table 4. Allelic diversity for each of the 24 loci MIRU-VNTR for 87 MDR-TB isolates | 45 |
| Table 5. Cumulative discriminatory index for 24-MIRU-VNTR loci and combined with spoligotyping. | 46 |
| Table 6. Information on the 12 CAS1-Kili Zambian strains. | 72 |
| Table 7. Similarity matrix showing core-SNP differences of the 12 SIT21/CAS1-Kili strains. SNPs differences between strains ranged from 1 to 26 SNPs. | 73 |
| Table 8. Number of L3.1.1 global strains from each country..... | 74 |
| Table 9. List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler..... | 75 |

ABBREVIATIONS

| | |
|---------------|--|
| DR | Direct repeat |
| EMB | Ethambutol |
| <i>gyrA</i> | Gene encoding DNA gyrase A subunit |
| <i>gyrB</i> | Gene encoding DNA gyrase B subunit |
| HIV | Human Immunodeficiency Virus |
| INH | Isoniazid |
| InhA | Enoyl-acyl carrier protein reductase |
| KatG | Catalase-peroxidase |
| <i>KatG</i> | Gene encoding catalase-peroxidase |
| Leu | Leucine |
| MDR | Multidrug-resistant |
| MGIT | Mycobacteria growth indicator tube |
| MIRU-VNTR | Mycobacterial interspersed repetitive units-variable number tandem repeats |
| PCR | Polymerase chain reaction |
| PE | Proline-glutamate |
| PPE | Proline-proline-glutamate |
| QUB | Queen's University Belfast |
| RIF | Rifampicin |
| RFLP | Restriction fragment length polymorphism |
| RNA | Ribose nucleic acid |
| RpoB | RNA polymerase β -subunit |
| RR | Rifampicin resistant |
| RRDR | Rifampicin resistance determining region |
| SIT | Spoligotype international type |
| SNP | Single nucleotide polymorphism |
| Spoligotyping | Spacer-oligonucleotide typing |
| STR | Streptomycin |
| TB | Tuberculosis |
| WHO | World Health Organisation |
| XDR | Extensively drug-resistant |
| ZN | Ziehl-Neelsen |

NOTES

1 . Chizimu J.Y, Solo E.S, Bwalya P, Kapalamula T.F, Akapelwa M.L, Lungu P, Shrestha D, Fukushima Y, Mukonka V, Thapa J, Nakajima C, Suzuki Y. Genetic Diversity and Transmission of Multidrug Resistant *Mycobacterium tuberculosis* strains in Lusaka, Zambia. *Int. J. Infect. Dis.* 2021

2. Chizimu J.Y, Solo E.S, Bwalya P, Tanomsridachchai W, Chambaro H, Shawa M, Kapalamula T.F, Lungu P, Fukushima Y, Mukonka V, Thapa J, Nakajima C, Suzuki Y. Whole-genome sequencing reveals recent transmission of multidrug-resistant *Mycobacterium tuberculosis* CAS1-Kili strains in Lusaka, Zambia *Antibiot.* 2021

PREFACE

Tuberculosis continues to be a major public health issue around the world. Over the previous years, progress has been recorded towards TB elimination, though the gains have been lost due to the negative impacts of the COVID-19 outbreak on tuberculosis. Thus, this has handicapped the WHO End TB Strategy by 2035. In 2020, 1.3 million HIV-negative people died from this curable and preventable disease, which was an 8% increase when compared to 2019 (WHO, 2021a). Therefore, the disease has remained a major cause of ill-health and mortality in many countries. The disease is worse in developing countries, especially those with a high prevalence of HIV/AIDS. In 2020, the WHO regions of South-East Asia, Africa, and the Western Pacific contributed 43%, 25%, and 18% of global TB cases, respectively. While the Eastern Mediterranean, the Americas, and Europe had lower percentages of 8.3%, 3%, and 2.3% of TB cases respectively. Besides, 86% of all estimated incident cases globally came from the 30 nations with the highest TB burden (Figure 1). Moreover, two-thirds of the global total were from eight countries that included India (26%), China (8.5%), Indonesia (8.4%), Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%) and South Africa (3.3%). Figure 2 shows the estimated TB incidence rates of 2020 by WHO.

In addition to the current negative impact of COVID-19 on tuberculosis management, drug-resistant tuberculosis has continued to be a threat to TB control globally. It's a major cause of death due to anti-microbial resistance. This is because its treatment involves the use of second-line anti-tuberculosis drugs that have more adverse events and expensive. Drug resistance develops as a result of the incorrect administration of antibiotics in the treatment of drug-susceptible tuberculosis. This improper usage is the consequence of a variety of behaviors, including the prescription of ineffective treatment regimens, poor compliance, and the failure to ensure that patients finish the entire course of treatment. The development of drug resistance in most cases is indicative of ineffective tuberculosis control programs (WHO, 2021b). WHO has defined cases of drug-resistant TB into five groups. These are isoniazid-resistant, rifampicin-resistant TB (RR-TB), multidrug-resistant TB (MDR-TB), pre-extensively drug-resistant TB (pre-XDR-TB), and extensively drug-resistant TB (XDR-TB). MDR-TB is when *M. tuberculosis* becomes resistant to both isoniazid and rifampicin. While when resistant to rifampicin and any fluoroquinolone (a class of second-line anti-TB drug) it's defined as pre-XDR-TB. In an event where *M. tuberculosis* becomes resistant to rifampicin, any fluoroquinolone, and at least one of the medicines bedaquiline and linezolid it is known as XDR-TB (WHO, 2021a), a more severe disease manifestation with complicated treatment.

In 2020, 157903 drug-resistant cases were recorded, including 132222 multidrug or rifampicin-resistant tuberculosis (MDR/RR-TB) cases and 25681 pre-XDR-TB or XDR-TB cases. This was a considerable decline (by 22%) from the total of 201997 drug-resistant tuberculosis cases diagnosed in 2019. Between 2019 and 2020, there were considerable decreases in the overall number of people newly diagnosed with TB (by 18%) and the total number of people diagnosed with bacteriologically proven pulmonary TB (by 17%). The reductions were attributed to the COVID-19 epidemic, which disturbed the systems for TB control. MDR/RR-TB continues to be an agonizing situation regarding its treatment success. Though an increment of 19% from 2012 was reported in 2018, the global treatment success of 59% was still low. This ranged from 56% in WHO European Regions to 69% in WHO African Regions.

Mycobacterium tuberculosis, the cause of tuberculosis, belongs to the order Actinomycetales. It was identified by Robert Koch in 1882. *Mycobacterium tuberculosis* is a non-motile, non-sporulating, rod-shaped, acid-fast bacillus with a slow growth rate. It is 1 to 4 μm in length, and 0.3 to 0.6 μm width. It is a member of the *Mycobacterium tuberculosis* complex (MTBC) grouped under *M. tuberculosis sensu stricto*. Other members of MTBC include *M. africanum*, *M. canetti*, *M. bovis*, *M. caprae*, *M. microti*, *M. pinnipedii*, *M. mungi*, and *M. orygis* (Figure 3a). MTBC members are closely related with 99.9% similarity in DNA sequence, but they are discriminated against each other by the existence of rare synonymous single-nucleotide polymorphisms (SNPs) (Smith, 2003). Several MTBC species have inherent host preferences, with some infecting particular animal species whilst others infect humans. For example, *M. bovis* has cattle, *M. caprae* (sheep and goats), and *M. pinnipedii* (seals and sea lions) as natural hosts. The primary causes of human TB are *M. tuberculosis sensu stricto* and *M. africanum*. These pathogenic mycobacteria are thought to have originated from early predecessors that thrived in a variety of environments and later gained the ability to persist intracellularly. MTBC, together with *M. canetti* and other "smooth strains," form a single and compact clonal group based on 16S rRNA sequencing. *M. canetti* and the other smooth strains have different features than the other members of the MTBC, such as producing smooth colonies with a shorter generation period. *M. prototuberculosis* is the term referring to these smooth strains, which are thought to represent the mycobacteria population that gave rise to MTBC (Gutierrez et al., 2005).

The hydrophobic cell wall is characteristic to *M. tuberculosis*. The cell wall has four main layers (Figure 4). Starting from inside to the outside of the cell, the layers are as follows; (a) inner plasma membrane, (b) the peptidoglycan–arabinogalactan complex (AGP), (c) an

asymmetrical outer membrane connected to AGP by mycolic acids, and (d) the external capsule (Kalscheuer et al., 2019).

The peptidoglycan–arabinogalactan complex (AGP) has mycolic acids which are unique to mycobacteria and have a role in the cell wall structure and function. While arabinogalactan forms a hydrophobic permeability barrier. The external capsule of the cell wall is composed of proteins, lipids, and polysaccharides. The cell wall of *M. tuberculosis* contributes to its specific characteristics regarding acid/alcohol fast nature, slow cell division, distinctive immunostimulatory capabilities, resistance to antimicrobial agents, detergents, and other environmental stressors (Daffé and Draper, 1997).

People get infected with *M. tuberculosis* through the inhalation of infected droplet nuclei from an infected individual. A single aerosol droplet can contain 1 to 400 bacilli which is more than the infectious dose of 1 to 200 bacilli (Balasubramanian et al., 1994). Once in the lungs, the bacilli are phagocytosed by alveolar macrophages. However, bacilli continue to multiply in macrophages and trigger a chemotactic response, which attracts more macrophages and other defense cells to the site. The inflammatory cells encompass the infection site and form a tubercle with infected macrophages in the core surrounded by epithelioid macrophages, foam cells, and multinucleated giant cells of the Langhans type, lymphocytes, and a fibrous capsule. The tubercle balances between infection containment in the host and *M. tuberculosis* protection from IFN-producing cells. The majority of the macrophages fail to eliminate bacteria and instead release enzymes that induce more inflammation that is harmful to the host. After some time, the tubercle undergoes caseous necrosis, and hence the dead macrophages release the bacilli, high lipid, and protein content. At this stage of the disease, symptoms may start to appear. However, the tubercle is hypoxic and aerobic bacilli do not grow well and hence remain dormant, a stage called latent tuberculosis. The bacilli survive in this state by metabolizing fatty acids, reducing active replication, and thickening cell walls (Boshoff and Barry, 2005). In individuals with competent immune systems, lesions become calcified and the infection is stopped at this stage or remains dormant for many years.

While in immune-compromised people the caseous region continues to grow by liquefaction resulting in an air-filled tuberculous cavity that supports bacilli growth. Liquefaction erodes the walls causing rupture of the tubercle releasing the bacilli into the bronchioles and bloodstream leading to disseminated tuberculosis called miliary tuberculosis. At this stage, the patient presents with symptoms. The disease usually affects the lungs but can involve other organs as in the case of extra-pulmonary tuberculosis. Symptoms include productive cough with blood-stained sputum due to damaged tissues, fever, night sweats,

fatigue, lack of appetite, and weight loss. On examination of the chest, they may have abnormal breath sounds and crepitations. It's worth noting that the bacilli can spread to the regional lymph nodes and hematogenous spread to other organs before the formation of these organized granulomas.

Usually, 5–10% of people with latent tuberculosis develop an active infection at some point in their lives (CDC, 2016) when the immunity gets suppressed for some reason. Therefore, the risk factors for having an active infection include comorbidities such as HIV/AIDS, diabetes, chronic renal disease, neoplastic disorders, undernutrition, and those receiving chemotherapy. Others are smoking and alcohol abuse disorders. Hence, patients presenting with such risk factors and symptoms related to tuberculosis should be screened for TB using any of the available diagnostic methods.

Tuberculosis has been diagnosed using a variety of techniques. Smear microscopy is widely used, especially in developing nations, for the detection of acid-fast bacilli despite having low sensitivity and specificity when compared to culture. In this method, the smear is fixed, stained with carbol-fuchsin, and decolorized with alcohol. Methylene blue is then used to counterstain the smear, giving the bacilli a pink appearance. These characteristics are due to the lipid-rich cell wall that does not readily take up the stain and resists decolorization when distained with an acid-alcohol wash. TB culture is considered the gold standard, though the technique takes weeks to months to get results. Therefore, rapid tests based on molecular markers such as Xpert MTB/RIF and GenoType MTBDRsl assay have been developed for rapid diagnosis (Kurbatova et al., 2013; Lacoma et al., 2012). Chest X-ray is another tool used in the diagnosis of tuberculosis. Nonetheless, even in patients with active infection, the chest X-ray result is sometimes negative. All patients diagnosed with TB are ideally started on the appropriate treatment with anti-tuberculosis drugs.

Anti-tuberculosis drug discovery, development, and treatment have been available since the 1940s, though the regimens have changed with time. The current treatment for susceptible tuberculosis is by the use of the first-line drugs, which are rifampicin, isoniazid, ethambutol, and pyrazinamide under the directly observed treatment short-course. The treatment is for 2 and 4 months for the intensive and continuation phases, respectively. Multiple drug therapies are applied to avoid the emergence of drug-resistant strains. In the event that *M. tuberculosis* becomes resistant to any of the first-line drugs, this is called drug-resistant tuberculosis.

The treatment of drug-resistant tuberculosis such as MDR/RR-TB includes the use of a shorter all-oral bedaquiline-containing regimen for 9–12 months duration. The regimen is

composed of 6 months of bedaquiline, together with 4 months of levofloxacin/moxifloxacin, pyrazinamide, ethambutol, isoniazid (high-dose), clofazimine, and ethionamide, and then followed by 5 months with levofloxacin/moxifloxacin, clofazimine, ethambutol and pyrazinamide. Patients must be fluoroquinolone susceptible and have not been exposed to the second-line TB medicines utilized in this regimen for more than one month. While in other patients longer treatments regimens are utilized. These include all three Group A antibiotics (levofloxacin or moxifloxacin, bedaquiline and linezolid) and at least one Group B antibiotic (clofazimine, and cycloserine or terizidone). Both Group B agents are included if only one or two Group A agents are used. Group C agents (ethambutol, delamanid, pyrazinamide, imipenem–cilastatin or meropenem, amikacin (or streptomycin), ethionamide or prothionamide, and p-aminosalicylic acid) are utilized in cases where Groups A and B drugs alone are unable to complete the treatment regimen (WHO, 2020).

In 1998 Cole ST et al. published the complete genome of *M. tuberculosis* H37Rv with approximately 4000 genes and 4.4 million base pairs (Cole ST et al.1998). This improved the understanding of drug resistance mechanisms to the most routinely prescribed anti-TB medications. It also revealed that specific gene changes were linked to drug resistance (Ramaswamy and Musser, 1998). When compared to other bacteria, *M. tuberculosis* acquires drug resistance mostly through spontaneous mutations in chromosomal genes, as opposed to horizontal transmission of mobile genetic elements such as transposons, plasmids, and integrons. Sub-optimal medication therapy facilitates the acquisition of drug resistance, resulting in a selection of resistant bacteria (Kochi et al., 1993). According to studies, most anti-tuberculosis medications have a mutation rate of 10^{-9} mutations per cell division. This rate, however, may vary based on the type of drug chosen. As a result, medications are administered in combination to lessen the chance of developing drug resistance. A mutant with two resistance mutations, for example, has a risk of 10^{-18} (Gillespie, 2007).

Resistance to isoniazid involves mutations in *katG* and *inhA* genes. Several mutations in those genes have been identified, though Ser 315 Thr amino acid change in *katG* has been the most prevalent, appearing in 50-93 percent of resistant clinical isolates. While mutations in an 81 bp drug resistance determining region (RRDR) of *rpoB* lead to varying levels of rifampicin resistance, with mutations like His 526 Asp, Asp 516 Val, and Ser 531 Leu being the most prevalent and seen worldwide. Other mutations in *rpoC* and outside the RRDR act as compensatory mutations.

Despite the discrepancy in reports concerning the mechanisms for ethambutol resistance, mutations in *embB*, especially at condon 306, have been found to be responsible for

50% of ethambutol resistant cases (Sreevatsan et al., 1997; Telenti et al., 1997). Some *embB* mutations have been linked to high levels of resistance, while others have been linked to low levels of resistance. Whereas, studies have reported up to 20% of susceptible strains with mutations in *embB* (Lee et al., 2004). The last but not the least first-line drug is pyrazinamide. The resistance mechanism to this drug involves mutations in *pncA*, mainly in the 561 bp region of the open reading frame or an 82 bp region of its putative promoter (Scorpio et al., 1997).

Patients with resistant strains to the first-line anti-TB drugs are treated with second-line drugs, which include the use of fluoroquinolones, aminoglycosides etc. Fluoroquinolones target *gyrA* and *gyrB*, which encode the DNA gyrase involved in DNA replication. Mutations in the quinolone resistance determining region (QRDR) mainly at codons 90, 91, and 94 of *gyrA* are implicated in drug resistance (Maruri et al., 2012; Palomino and Martin, 2014). Additionally, *M. tuberculosis* strains become resistant to aminoglycosides (Kanamycin and Amikacin) by acquiring mutations at positions 1400, 1401 and 1483 of the *rrs* gene (Palomino and Martin, 2014; Suzuki et al., 1998).

However, some of the drug-resistance mutations in genes such as KatG (Ser 315 Thr) and *rpoB* (Ser 450 Leu) of *M. tuberculosis* have an impact on its fitness. Reports have hypothesized a reduced ability to spread and cause disease among such strains. Therefore, *M. tuberculosis* acquires compensatory mutations to mitigate the negative effects of drug resistance mutations and hence preserve the ability of the bacteria to spread (Brandis et al., 2012; Comas et al., 2011). It is cardinal to know the drug resistance patterns of the circulating strains in a particular area to guide the appropriate treatment regimens and control measures. Hence, the combination of drug susceptibility testing and molecular epidemiology plays an important role in drug resistance surveillance.

Molecular epidemiological studies facilitate the understanding of transmission dynamics, characteristics of the circulating genotypes, and effectiveness of the TB control measures (Besser, 2013). Besides, molecular epidemiology can facilitate the comparison of strains from various geographical regions and provide evolutionary insight, in addition to distinguishing reinfection from reactivation and detecting laboratory cross-contamination. This is achieved through the application of various molecular genotyping methods that utilize the polymorphic sites at the nucleotide or gene level in the tuberculosis genome. Polymorphic sites include SNPs, clustered regularly interspaced short palindromic repeats (CRISPR), variable number of tandem repeats (VNTR), and insertion sequences (IS).

Spoligotyping is one of the genotyping procedures. This is aimed at polymorphisms in the direct repeat (DR) region of *M. tuberculosis*. DR region is composed of multiple copies of

a conserved 36-base-pair sequence (DR) which are separated by 35-41 unique spacer sequences (Figure 5a). It involves PCR amplification of the DR region using specific primers and hybridizing on a membrane. The presence and absence of the 43 unique spacer DNA sequences provide the basis for distinguishing strains (Kamerbeek et al., 1997). It has less discriminatory power when compared to mycobacterial interspersed repetitive units-variable number tandem repeat (MIRU-VNTR).

MIRU-VNTR typing utilizes the allelic variations in the VNTR loci in *M. tuberculosis* genome. The genome has 41 MIRU loci consisting of 40-100 bp repetitive sequences (Supply et al. 2006) (Figure 5b). The loci that are polymorphic are considered as VNTR loci. It's also a PCR-based assay in which MIRU-VNTR loci are amplified, visualized by gel electrophoresis, and molecular weights determined. The molecular weights are interpreted as the number of tandem repeats. The discriminatory power increases depending on the number of loci used, with the standard 24 MIRU-VNTR loci being the most discriminatory when compared to 15 and 12 MIRU-VNTR loci. When combined with spoligotyping the discriminatory power increases to almost that of IS6110 restricted fragment length polymorphism (RFLP).

IS6110 RFLP is the gold standard for studying MTBC strain relatedness by exploiting variations in restriction sites in the DNA of different strains. This variability is enough to yield the RFLP utilized in fingerprinting. A restriction enzyme (PvuII), digests the IS6110 element resulting in DNA fragments that are separated by gel electrophoresis and visualized by probing with an IS6110 probe. The IS6110 probe hybridizes to the right of the PvuII cleavage site. The blot containing HaeII-digested ϕ X174DNA is then compared to the *M. tuberculosis* reference strain to generate unique fingerprints (Moström et al., 2002). IS6110 has 0–25 copies, and their positions on the *M. tuberculosis* chromosome differ from isolate to isolate (Soolingen et al. 1991). It has a higher discriminatory power when compared to MIRU-VNTR and spoligotyping, but lower than whole-genome sequencing (WGS). The advantages and disadvantages of each particular genotyping method are listed in the Table 1.

WGS is an ultimate high-resolution technique for determining strain relatedness, transmission drug resistance patterns, genomic evolution, and virulence factors. Other methods target polymorphic sites in only less than 1% of the TB genome. Hence, they have limited discriminatory power in differentiating closely related strains and are prone to homoplasmy. Briefly, the procedure involves library preparation in which there's fragmentation of DNA and ligation of adapters. These are then attached to the flow cell and amplified to increase the signal emission. The signal is generated by the incorporation of a nucleotide/oligonucleotide during sequencing. The output raw sequences are then compared to the reference for drug-resistance

profile determination, transmission, evolution analysis, and lineage identification (Oudghiri et al., 2018).

MTBC has seven major human-adapted lineages, which are *M. tuberculosis sensu strictu* [Lineages 1 (L1) to 4], Lineage 7 (L7), and *M. africanum* (Lineages 5 to 6). In humans, these lineages are able to maintain full infection, disease, and transmission cycles (Ernst, 2012). Lineages 2 to 4 are the modern, while L1, L5 to L7 are termed the ancient lineages based on the genomic region TbD1 deletion. The TbD1 region is deleted in modern lineages but intact in ancient lineages (Gagneux, 2017). These lineages have been shown to have specific geographical distributions, with L2 and L4 being global, L1 around the Indian Ocean, and L3 in East Africa, central and South-Asia (Figure 3) whereas L5 (*M. africanum* West Africa 1) and L6 (*M. africanum* West Africa 2) are restricted to certain geographical areas, mainly West Africa. Lineages 1, 2, 3, and 4 are also known as Indo-Oceanic, East-Asian, Central Asian Strain (CAS), and Euro-American lineages, respectively. Other lineages, such as L7, have been restricted to the horn of Africa. The geographical preferences of MTBC lineages are a result of the higher fitness of the pathogen in a particular host population it has co-evolved with (Gagneux, 2012). However, some strains are now present in areas where they were originally in existence due to the migration of people and the evolution of tuberculosis over time. Furthermore, the lineages differ from each other as a result of varied compositions of single nucleotide polymorphisms (SNPs), insertion and deletion (indels), mobile and repetitive elements, large genomic deletions, and large duplications. The most diverse lineage is L1, with an average of 730 SNPs between any two L1 strains. While L7 is the least diverse, with an average of 230 SNPs between any two L7 strains.

The information on the circulating lineages in a specific region is important as different MTBC strains have different immunogenicity, virulence, and transmissibility (Coscolla and Gagneux 2014). It is also a factor that determines host response and the emergence of drug resistance, control, and clinical outcome of pulmonary and extra-pulmonary tuberculosis (Napier et al., 2020).

In Zambia, tuberculosis is among the major causes of morbidity and top ten causes of mortality (Ministry of Health, 2017). Zambia recorded a total TB incidence of 319/100,000 population in 2020 (WHO, 2021c). The trends for TB incidence, new and relapse TB cases notified, and HIV-positive/TB incidence have been relatively declining over the past decade, mainly because of a relatively well-established TB control program and the involvement of other stakeholders (Figure 6). Additionally, the treatment success for new and relapsed cases

registered in 2019 was 89%. However, Zambia is among the global high-burden countries for TB, HIV-associated TB, and MDR/RR-TB according to WHO (WHO, 2021a) (Figure 1).

Despite the global MDR/RR-TB burden remaining relatively stable, Zambia had a 2.8 times increase in the estimated percentage of TB cases with MDR/RR-TB among the new pulmonary TB cases for the period 2015 to 2018 (WHO, 2016, 2019a) (Figure 7). This was suggestive of possible transmission of primary MDR/RR-TB. In addition, previous studies and routine surveillance in Zambia revealed an increase in MDR-TB (Kapata et al., 2013; Mulenga et al., 2010; Solo et al., 2021). Similar to the global picture, MDR-TB in Zambia has been associated with a lower treatment success rate and high mortality when compared to pan susceptible tuberculosis. Nevertheless, MDR case surveillance to understand the circulating strains and their transmission patterns has been inadequate, leading to limited information on the subject. Therefore, to address this gap, this dissertation focused on the molecular epidemiological analysis of multi-drug resistant *Mycobacterium tuberculosis* in Lusaka, Zambia.

There are two chapters in this dissertation. I determined the genetic diversity and transmission patterns of multidrug-resistant *M. tuberculosis* in Lusaka, Zambia, in the first chapter. This was in response to an increase in routine surveillance reports of MDR-TB, but insufficient information on its transmission and diversity. In this chapter, it was revealed that to a larger degree, the MDR-TB spread was due to recent transmission rather than the independent acquisition of MDR. Further, clonal expansion of spoligotype international types (SIT) 21 CAS1-Kili (SIT21/CAS1-Kili) and SIT20 Latin American-Mediterranean one (LAM1) strains were implicated for this spread. Therefore, TB control programs involving genotyping coupled with conventional epidemiological methods to guide measures for stopping the spread of MDR-TB were recommended.

In the second chapter, I evaluated recent transmission among the lineage 3 (CAS1-Kili) strains that were linked to and responsible for MDR *M. tuberculosis* spread in the first chapter. A high-resolution technology, WGS was used to distinguish these strains. The CAS1-Kili strains were closely related, implying recent transmission as they exhibited low SNP variabilities. Furthermore, the phylogenetic analysis showed that Zambian strains were related to those from Tanzania, Malawi, and the United Kingdom. As a result, the chapter recommends using WGS in addition to standard epidemiological methodologies to better understand MDR-TB transmission.

Table 1. Advantages and disadvantages of molecular genotyping methods

| Advantages | Disadvantages |
|--|--|
| Spoligotyping | |
| <ul style="list-style-type: none"> ▪ Rapid, repeatable, robust and cost-effective ▪ Simple to compare findings from different laboratories ▪ Viable culture is not needed ▪ Small amount of DNA needed ▪ No need for DNA purification ▪ It is able to differentiate between re-infection and reactivation in patients who relapse during or after chemotherapy | <ul style="list-style-type: none"> ▪ Poor discriminatory power hence overestimates clustering when compared to MIRU-VNTR and IS6110 ▪ Is unable to distinguish between several common strain families, particularly Beijing |
| Mycobacterial Interspersed Repetitive Unit-Variable Number of Tandem Repeats (MIRU-VNTR) | |
| <ul style="list-style-type: none"> ▪ Viable culture is not needed ▪ Small amount of DNA needed ▪ Rapid, reproducible and less expensive when compared to RFLP ▪ It has a higher discriminatory power than spoligotyping ▪ Easier to compare findings from different laboratories | <ul style="list-style-type: none"> ▪ In outbreak settings, it has limited ability to differentiate between relapse and re-infection ▪ Limited ability to differentiate some lineages eg Beijing ▪ Sometimes it's difficult to obtain a full MIRU-VNTR pattern ▪ Unclear stability or mutation rate of the loci |

| | |
|--|--|
| <ul style="list-style-type: none"> ▪ IS6110 restriction fragment length polymorphism typing (RFLP) | |
| <ul style="list-style-type: none"> ▪ High discriminatory power in differentiating epidemiologically unrelated strains especially in strains with multiple IS6110 insertion sites ▪ Thoroughly tested technique ▪ The polymorphic sites have high stability due to slow insertion rate | <ul style="list-style-type: none"> ▪ Time-consuming and labor-intensive ▪ Requires a viable culture and high DNA quantity and digestion with restriction enzymes ▪ High level of technical expertise is needed ▪ Difficulties in reproducibility and comparability ▪ Poor discriminative power for strains with less than five copy number of IS6110 |
| <ul style="list-style-type: none"> ▪ Whole genome sequencing (WGS) | <ul style="list-style-type: none"> ▪ |
| <ul style="list-style-type: none"> ▪ Ultimate highest discriminatory power in delineating closely related strains ▪ Can infer the likely direction of transmission without prior recourse to epidemiological data ▪ Provides high levels of evolutionary insight | <ul style="list-style-type: none"> ▪ It's expensive and has a low turn-around time ▪ Programs for standardization and quality assurance have yet to be established. ▪ High level of technical expertise is needed ▪ Complicated bioinformatics and specialist software for storage and analysis ▪ standardization as well as quality assurance programs are yet to be established |




Figure 1. Figure showing Zambia among the three global lists for high-burden countries for TB, HIV-associated TB and MDR/RR-TB adapted from WHO 2021b. Each of the three lists is represented by a specific color; blue for MDR/RR-TB, red for TB and orange for TB/HIV. Some countries including Zambia, are in more than one list as shown by the overlapping areas.




Figure 2. WHO TB incidence rate estimates for the year 2020 adapted from WHO 2021b. The map was shaded according to the incidence per 100,000 population per year as indicated in the legend.





Figure 3. Phylogenetic tree showing the seven human and animal adapted lineages rooted to *M. canetti* adapted from Coscolla 2017. (b) Global map showing the distribution of four of the seven lineages (b) and (c) sub-lineages. (Data adapted from Chihota et al. 2018 and SITVIT2 WEB Database available on <http://www.pasteur-guadeloupe.fr:8081/SITVIT2/index.jsp>). Some lineages are widely distributed while others are restricted to certain geographic regions.

(c)






Figure 4. Mycobacterium cell wall structure adapted from Kaiser 2019.






Figure 5. Diagram illustration the genotyping methods utilized in this dissertation. (a). Spoligotyping (Kamerbeek et al., 1997) (b). MIRU-VNTR (Supply et al., 2006) (c). Whole genome sequencing adapted from Disease Profiling Project 2018.



(c) **Whole genome sequencing**






Figure 6. Zambia tuberculosis incidence and mortality estimates per 100,000 population for the period 2000 to 2020 (WHO, 2021a).




Figure 7. Estimated TB cases with MDR/RR-TB among the new and previously treated cases (WHO, 2019a, 2018, 2017, 2016).

CHAPTER 1

Genetic Diversity and Transmission of Multidrug Resistant *Mycobacterium tuberculosis* strains in Lusaka, Zambia

Introduction

Tuberculosis exacerbated by the emergence of MDR strains remains a major public health challenge in many countries worldwide. MDR-TB is caused by *M. tuberculosis* that is resistant to isoniazid and rifampicin, the most effective first-line drugs. Its treatment involves the use of second-line drugs which are expensive and have more side effects. MDR-TB is associated with a low treatment success rate and high mortality (WHO, 2019b). Moreover, MDR-TB has paused a threat to the achievement of End TB strategy by 2035 (2019 WHO, 2019). Tuberculosis with an incidence of 333/100,000 is among the top ten causes of mortality in Zambia (Ministry of Health, 2017; WHO, 2021d). Reports indicated the low occurrence of MDR-TB in the country (Ministry of Health, 2017; Mulenga et al., 2010; WHO, 2019b) though an incremental trend of notified cases per year was observed (Kapata et al., 2013). Drivers of MDR-TB in Zambia may be speculated to be late diagnosis and initiation of treatment due to fewer diagnostic centers, poor compliance among patients, and cross-border movements of people from high burden TB countries for economic activities and refuge.

Previous studies have indicated the predominance of Euro-American and East Asian lineages, the lineage 4 (L4) and 2 (L2), respectively, circulating in the southern African region (Chihota et al., 2018; Mbugi et al., 2016). Molecular genotyping methods such as spoligotyping and MIRU-VNTR are utilized in the understanding of genetic diversity and spread of *M. tuberculosis* (Said et al., 2012). Though differing in their ability to differentiate between unrelated strains, their combination provides a higher diversity index.

A few studies in Zambia have described *M. tuberculosis* diversity using 15 loci MIRU-VNTR in Ndola and Namwala districts (Malama et al., 2014; Mulenga et al., 2010). Further, an association of drug resistance with specific genotypes in Lusaka based on spoligotyping was previously described (Solo et al., 2021). Nevertheless, information on the transmission of MDR *M. tuberculosis* strains in Lusaka, Zambia is still inadequate. Hence, the current study explores this gap to guide the implementation of TB control interventions.

Materials and methods

Sample collection, processing, DNA extraction

The study utilized 85 MDR-TB clinical isolates collected and banked at the University Teaching Hospital (UTH) TB laboratory in Lusaka, Zambia, from 2013 to 2017. UTH TB laboratory is one of the three TB culturing facilities in the country covering over one-third of the country's population (Figure 8). Sample decontamination, sub-culturing, and drug susceptibility testing to the first-line drugs (rifampicin, isoniazid, ethambutol, and streptomycin) using BACTEC™ 960 MGIT™ (Mycobacteria Growth Indicator Tube) system (Becton Dickson & Co., Franklin Lakes, NJ, USA) were done following the manufacturer's instructions. The recommended critical concentrations by the kit manufacturer (Becton, Dickinson, and Company) of 0.1, 1.0, 1.0, and 5.0 µg/mL for isoniazid, rifampicin, streptomycin and ethambutol respectively were followed. DNA was extracted as described previously (Solo et al. 2020). The demographic information such as residence, age, and year of collection for the strains was captured after a review of laboratory registers.

Drug-resistance associated gene sequencing

Briefly, sequencing for *rpoB*, *katG* genes, and *inhA* promoter region was conducted using the specific primers to detect mutations in respective genes as previously described (Solo et al. 2020) and resolute that isolates were genotypically multidrug-resistant.

Spoligotyping

Sub-lineages were identified using spoligotyping as described elsewhere (Kamerbeek et al. 1997; Solo et al. 2021). Briefly, PCR amplified the DR region using primers to generate different-sized amplicons which were hybridized to a set of 43 complimentary immobilized oligonucleotides on a membrane to detect the presence or absence of spacers. The resulting binary spoligotyping patterns were evaluated using the SITVIT2 WEB Database available on <http://www.pasteur-guadeloupe.fr:8081/SITVIT2/index.jsp>.

MIRU-VNTR typing

Strains were further analyzed using 24 loci (MIRU02, MIRU04, MIRU10, MIRU16, MIRU20, MIRU23, MIRU24, MIRU26, MIRU27, MIRU31, MIRU39, MIRU40, Mtu04, Mtub21, Mtub30, Mtub39, exact tandem repeats (ETR)-A, ETR-B, ETR-C, ETR-F, Queen's University Belfast (QUB) 11a, QUB11b, QUB26, and QUB4156) to determine their genetic relatedness. To improve the discriminatory power, two of the 24 loci (Mtub29 and Mtub34) reported by Supply et al. 2006 were replaced with ETR-F and QUB11a (Shah et al., 2017). Briefly, each locus was amplified individually using the specific primers for the flanking regions as described Supply et al. 2006. The PCR products were identified by gel electrophoresis with a 50 bp DNA ladder stained with ethidium bromide to visualize the bands for molecular weights determination. The number of tandem repeats was determined by comparing the size of the amplicons to the corresponding base pairs on the conversion table.

Hunter-Gaston Discriminatory Index (HGDI) for the respective loci was determined using the formula;

$$\text{HGDI} = 1 - \frac{1}{N(N-1)} \sum_{j=1}^s x_j (x_j - 1)$$

where N is the total number of studied isolates, x_j is the number of isolates with j^{th} pattern and s is the number of genetic patterns (Hunter, 1990; Hunter et al., 1988). The discriminatory index was defined as high when $\text{HGDI} > 0.6$, moderate $0.3 < \text{HGDI} < 0.6$, and $\text{HGDI} < 0.3$ as poor. The cumulative HGDI was calculated by adding the MIRU-VNTR loci cumulatively starting with the highest and ending with the lowest discriminatory locus. The corresponding clustering rates, cluster size, and patterns identified according to each number of loci used were also calculated. This was done using BioNumerics and the resulting identified patterns were then used to calculate HGDI using the above formula. I further compared the cumulative HGDI for the selected 9 and 15 high discriminatory loci among the major SITs and all the strains in the study to propose a convenient set of loci that may be used for MDR-TB genotyping in this area.

Phylogenetic analysis

The resulting MIRU-VNTR profiles were analyzed using *MIRU-VNTRplus* (Allix-Beguec et al., 2008; Weniger et al., 2010) and visualized using *ggtree* package in R-studio (Team, 2020; Yu, 2020; Yu et al., 2018, 2017). To visualize the evolutionary relationships of the strains, a dendrogram was constructed by an unweighted pair group method with arithmetic averages (UPGMA) based on 24 loci MIRU-VNTR and spoligotyping patterns. Further, the minimum spanning tree (MST) was calculated using 24-loci MIRU-VNTR data with a single locus variant as the maximum locus difference within a clonal complex using BioNumerics version 7.6 (Applied Maths, Sint-Martens-Latem, Belgium). Overall, a cluster was defined as 2 or more strains with identical spoligotyping and/or MIRU-VNTR profiles. Clustering rate was calculated using the formulae n_c/N , where n_c is the number of clustered strains, and N is the total number of strains analyzed.

Comparison of CAS1-Kili and LAM1 strains

The SIT21/CAS1-Kili and SIT20/LAM1 strains from the SITVIT2 database which had standard 12 MIRU-VNTR loci and spoligotyping information, together with our strains were considered for phylogenetic analysis because of their association with MDR in Zambia. Other loci were excluded due to the non-availability of information from the database for many strains. Three and eleven more strains were obtained from Mbugi et al 2015 and Perdigão et al 2017 respectively. As a result, together with our strains, a total of 101 CAS1-Kili and LAM1 strains were analyzed.

Detection of RD-Rio sub-lineage strains

Further, lineage 4 strains were subjected to multiplex PCR for RD-Rio sub-lineage determination. Briefly, multiplex PCR was done using specific primers following David *et al* (2012). The presence of RD-Rio deletion or wild type was determined by the presence of 530 bp or 1175 bp bands, respectively after gel electrophoresis.

Ethical approval

The study was approved by the Zambia National Research Authority, ERES Converge Ethical committee and permission was granted by the University Teaching Hospital management.

Results

Demographic profile

The majority 65% (55/85) of strains were from males while 32% (27/85) from female patients. The age range was 9 to 75 years with a median of 33 years old. Most of the strains were from Lusaka 69% (59/85), and 22% (19/85) were from referred patients from outside Lusaka (from towns such as Mongu, Kafue, Chongwe, Kabwe, Sesheke, and Monze). While for 4% (3/85) patients' information was missing for sex and 8% (7/85) for age and residence, respectively.

Drug-resistance associated gene sequencing

All samples were confirmed to be multidrug resistant by the presence of resistance-associated mutations. Mutations in the *rpoB* gene among the strains included Ser 531 Leu (54%, 46/85) followed by His 526 Tyr (11%, 9/85), and others had mutations in other codons including double mutations and deletions. Whereas all of the strains had Ser 315 Thr mutation in *katG* and no mutation in the *inhA* promoter region as described previously by Solo et al. 2020 and in Figure 9.

Spoligotyping

Among the 85 samples, 5 sub-lineages; LAM 48% (41/85), CAS 29% (25/85), T 14% (12/85), X 6% (5/85) and Harlem 2% (2/85) were identified by spoligotyping (Table 2). The most predominant SIT was SIT21/CAS1-Kili 29% (25/85) followed by SIT59/LAM11-ZWE 19% (16/85). In addition, 11 distinct patterns were identified with a clustering rate of 99% (Table 2).

MIRU-VNTR genotyping and phylogeny

Two strains had multiple bands in more than two loci, suggestive of mixed infection and thus, were excluded from the analysis. Hence, 83 strains were considered for further analysis. From the 83 MDR-TB strains, 24-loci MIRU-VNTR identified 47 genotype patterns with the clustering rate of 63%. The number of strains per cluster ranged from 2 to 9. The clustering rates among the major spoligotypes SIT20/LAM1, SIT21/CAS1-Kili, and

SIT59/LAM11-ZWE based on 24-loci MIRU-VNTR were 75%, 76%, and 67%, respectively (Figure 10 and table 3).

The 24 loci varied in allelic diversity ranging from 0.0 to 0.8 among all our study strains as shown in Table 4. The 10 loci (MIRU10, MIRU16, QUB11b, ETR-A, MIRU23, MIRU26, MIRU31, QUB11a, QUB26, and QUB4156) and 4 loci (MIRU02, MIRU04, MIRU20, and MIRU24) exhibited high and low diversities among the strains in this study respectively. Besides, alias ETR-A showed no bands after gel electrophoresis for 96% of SIT 21/CAS1-Kili isolates (Table 4).

In addition, the first 15 high discriminatory loci varied slightly in the discriminatory index when compared to 24 MIRU-VNTR loci, (cumulative HGDI: 0.965 vs 0.973). Further, the combination of the two genotyping methods (24-MIRU-VNTR and spoligotyping) yielded the same clustering rate and cumulative HGDI as when 24-MIRU-VNTR was applied alone (Table 5). While, among the predominant SITs 59/LAM11-ZWE and 21/CAS1-Kili, the combined methods had cumulative HGDI of 0.914 and 0.833 respectively as shown in Table 3. The minimum spanning tree (MST) grouped the strains in 7 clonal complexes. The largest clonal complex consisted of clades, SIT21/CAS1-Kili with 24 isolates followed by SIT20/LAM1 with 10 isolates (Figure 10).

Comparison of CAS1-Kili and LAM1 strains

Zambian CAS1-Kili strains had identical 12-loci MIRU-VNTR and spoligotyping patterns with many strains from Somali, a strain from Ethiopia, Sudan, and South Africa as shown in Figure 12. While Zambian SIT20/LAM1 strains formed a monophyletic clade separate from other African strains.

Detection of RD-Rio sub-lineage strains

Among the 58 strains from lineage 4, 66% (38/58) were classified as RD-Rio sub-lineage strains by multiplex PCR. All the strains that had RD-Rio deletion belonged to the LAM clade. This included all LAM1 and LAM11-ZWE strains. Two strains from SIT42/LAM9 did not belong to RD-Rio sub-lineage. While two other strains from non-LAM (H1 clade) had no bands visualized on gel electrophoresis (Figure 13).

Discussion

Despite the emergence of MDR-TB and increasing cases in routine surveillance systems (Kapata et al., 2013), there is limited information regarding genetic diversity and transmission of MDR *M. tuberculosis* in Zambia. Moreover, drug susceptibility testing (DST) is not routinely done on all TB patients, thus, reported cases are based on selected DST done after clinicians' recommendations which is likely to underestimate the prevailing situation regarding MDR-TB. Therefore, this called for the study to elucidate the transmission phenomenon of MDR *M. tuberculosis* strains in Zambia.

Among the study strains, spoligotyping revealed a clustering rate of 99%. This was not surprising as this genotyping method may overestimate clustering due to its lower discriminatory power or was as a result of some selection bias in the strains. While 24 loci MIRU-VNTR delineated the 11 spoligotypes into 47 unique patterns, 16 clusters with a clustering rate of 63%. This is because MIRU-VNTR is superior to spoligotyping, and prevents homoplasmy (Mokrousov et al., 2016; Supply et al., 2006).

Studies have described TB transmission based on clustering of strains using spoligotyping and MIRU-VNTR profiles (Easterbrook et al., 2004; Hamblion et al., 2016; Mulenga et al., 2010; Xu et al., 2018). Generally, strains with identical and unique genotypic profiles are as a result of recent transmission and independent acquisition of MDR, respectively. Hence, the clustering rate of 63% by 24 loci MIRU-VNTR and spoligotyping was suggestive of recent transmission playing a major role in the spread of MDR-TB. The limited number of reports applying 24-MIRU-VNTR on MDR-TB strains in Africa made it difficult to compare directly the clustering rates with other studies. Nevertheless, the clustering rate from this study was higher than other reports from Morocco (0%), Pakistan (15%), and China (33.1%) (Bakuła et al., 2019; Luo et al., 2019; Oudghiri et al., 2021). The recent transmission may be attributed more to the subfamilies SIT21/CAS1-Kili and SIT20/LAM1 as they formed the largest clonal complexes when compared to SIT59/LAM11-ZWE and others as shown in Figure 10. Moreover, all SIT20/LAM1 strains had KatG Ser315Thr and RpoB Ser 531 Leu mutations as shown in Figure 9. This combination of low-fitness-cost mutations has been described to increase transmission of MDR strains of the modern Beijing sublineage (Li et al., 2017).

Further, SIT21/CAS1-Kili and SIT20/LAM1 were previously reported to be associated with MDR-TB in Zambia (Solo et al. 2021). Therefore, having identical genotypic profiles and mutation combinations among some strains from SIT21/CAS1-Kili and SIT20/LAM1 is

indicative of clonal expansion of MDR-TB by these clades. Moreover, SIT20/LAM1 has been reported of having high proportions of strains among XDR-TB while, SIT21/CAS1-Kili has been associated with MDR-TB (Agonafir et al., 2010; David et al., 2012; Perdigão et al., 2019). Besides, the occurrence of MDR-TB in children in this study is a sign of active ongoing transmission in this area. Four percent (3/85) of patients were less than 15 years old and the majority (73%) were below the age of 40 years. The median age was 33 years similar to other studies in southern Africa (Sagonda et al., 2014; Said et al., 2012). On the other hand, some strains from patients living outside Lusaka, clustered with those from within the city (Figure 9). This may be attributed to the fact that patients referred from distant hospitals usually seek residence from relatives near the hospital to reduce on logistical costs which in turn facilitates the transmission of MDR-TB. Therefore, timely and effective contact tracing may reduce MDR-TB transmission through this mode. Further, two patients were supposedly family members as they had the same surnames and from within Lusaka, with samples collected in the space of 3 years but were clustered with the same mutations for rifampicin (RpoB Leu 511 Arg, Asp 516 Tyr) and isoniazid (KatG Ser315Thr) resistances as well as same spoligotyping and MIRU-VNTR patterns. However, a proportion of singletons illustrated that the conversion to MDR within each patient, such as in reactivation cases of latent tuberculosis, was also contributing to the MDR-TB population structure.

There were marginal differences regarding the discriminatory indices for 15 and 24 loci MIRU-VNTR (Table 3) in agreement with other studies (Perdigão et al., 2017; Silva et al., 2014). However, the discriminatory index of each locus differs according to geographical location and circulating strains in a region (Supply et al., 2006). Thus, the 24-loci were assessed to give a comprehensive analysis for the proposal of the loci set for MDR *M. tuberculosis* genotyping in this region. This was to suggest a set that is less labor-intensive and cheaper rather than 24 MIRU-VNTR loci. Hence, sets of the first 9 and 15-highly discriminatory MIRU-VNTR loci were suggested to be utilized for epidemiological and phylogenetic studies in this resource-limited region respectively (Table 3 and 5) (Hunter et al., 1988).

The three major clades SIT59/LAM11-ZWE, SIT21/CAS1-Kili, and SIT20/LAM1 varied markedly in their diversity indices with HGDI of 0.91, 0.83, and 0.67 respectively based on combined 24 MIRU-VNTR and spoligotyping (Table 3). The relatively lower HGDI for SIT21/CAS1-Kili and SIT20/LAM1, when compared to SIT59/LAM11_ZWE, emphasize the spread of these strains in this population. Nevertheless, more discriminatory methods such as WGS can elucidate more accurately the recent transmission of these clades.

The study showed lineage 4 and 3 as the major MDR *M. tuberculosis* strains in Zambia. The predominance of LAM clade was expected as this is the most common spreading strain for drug-susceptible tuberculosis in this region (Mulenga et al., 2010). Despite limited studies focusing on MDR-TB in Zambia and its neighboring countries, other studies in the southern African region had similar findings of LAM been predominant among MDR-TB strains (Namburete et al., 2020; Sagonda et al., 2014). Moreover, reports have indicated that lineage 4 predominates across Africa while lineage 3 occurs in larger proportions in the eastern than southern regions of Africa (Chihota et al., 2018). On the other hand, many studies on MDR *M. tuberculosis* from South Africa which doesn't share any borders with Zambia, had Beijing as the most common genotype with low occurrences of CAS clade below 5% (Figure 11) (Bhembe and Green, 2020; Chihota et al., 2012). Our current study revealed a relatively higher percentage (29%) of CAS sub-family than other south African countries among MDR *M. tuberculosis* strains (Figure 11). The CAS clade is more common in Tanzania which borders Zambia. The high percentage in this study is suggestive of the spread of the strain possibly due to migration of people because of trade with neighboring East African countries like Tanzania. Further, Zambia hosts and has incorporated thousands of refugees from Burundi and Rwanda (East African countries) into the local community (Commissioner and Grandi, 2019). Moreover, CAS1-Kili strains from this study had the same spoligotyping and standard 12-loci MIRU-VNTR patterns as those from Ethiopia, Sudan, Somali, and South Africa as shown in Figure 12. This may be suggestive of possible relations between these strains or due to poor discrimination of spoligotyping and standard 12-loci MIRU-VNTR genotyping methods.

In this study, 95% (38/40) of LAM strains had 1 tandem repeat in MIRU40, and 2 tandem repeats in MIRU2 loci (Figure 13), a VNTR signature for RD-Rio/RD 174 sub-lineages (Lazzarini et al., 2007; Mokrousov et al., 2016). All the 38 LAM strains were confirmed to belong to RD-Rio sub-lineage by multiplex PCR. The RD-Rio sub-lineage is common in Brazil and Portugal and has been associated with high transmissibility, MDR, and severe form of TB (David et al. 2012; Lazzarini et al. 2007; Mokrousov et al. 2016; De Almeida et al. 2019). It may be speculated that the ancestral strain might have come to Zambia through neighboring former Portuguese colonies such as Mozambique and Angola, which then gave rise to LAM11-ZWE that for some reason became endemic in this region (Brynildsrud et al., 2018; Mokrousov et al., 2016). Moreover, LAM1 and LAM9 spoligotypes are reported in high prevalence among LAM strains in Angola while LAM11_ZWE and LAM9 in Mozambique (Perdigão et al., 2017; Viegas et al., 2010). Mozambique and Angola had inadequate information on RD-Rio sub-lineage. Nevertheless, reports for RD174 that usually coexists with RD-Rio deletion were

found in these countries, (Mokrousov et al., 2016; Namburete et al., 2020; Perdigão et al., 2017) suggesting the likely presence of the RD-Rio sublineage.

Study limitations

Detailed epidemiological data and treatment history were inadequate. Hence, this affected a thorough evaluation of the spread and association with HIV/AIDS in the affected patients and communities. In addition, the smaller sample size hindered the generalization of the results. Hence, a large population study utilizing WGS, if possible, is needed to provide a comprehensive analysis of the circulating MDR *M. tuberculosis* strains.

Conclusion

The study revealed a high clustering rate that was suggestive of a large degree of MDR-TB spread attributed to recent transmission than independent acquisition of MDR. A 9-loci MIRU-VNTR was proposed to be utilized for screening of MDR *M. tuberculosis* lineages in this area to reduce on labor and cost associated with 24-MIRU-VNTR loci. Further, the study illustrated the clonal expansion of SIT20/LAM1 and SIT21/CAS1-Kili indicating their major role in the spread of MDR-TB in Lusaka Zambia. Therefore, this study recommends that TB control programs focusing on genotyping coupled with other measures such as early diagnosis, monitored treatment, and contact tracing of MDR-TB patients must be enhanced. This will facilitate the understanding of the transmission dynamics of MDR-TB and hence guide the implementation of appropriate control measures.

Summary

Zambia is among the 30 high tuberculosis burden countries in the world. Despite increasing reports of MDR-TB in routine surveillance, information on the transmission of MDR *Mycobacterium tuberculosis* strains is largely unknown. This study elucidated genetic diversity and transmission of MDR *M. tuberculosis* strains in Lusaka, Zambia. Eighty-five MDR *M. tuberculosis* samples collected from the year 2013 to 2017 at the University Teaching Hospital were used. Drug-resistance associated gene sequencing, spoligotyping, 24-loci MIRU-VNTR, and multiplex PCR for RD-Rio sub-lineage identification were applied.

Clades identified were LAM (48%), CAS (29%), T (14%), X (6%) and Harlem (2%). Strains belonging to SITs 21/CAS1-Kili and 20/LAM1 formed the largest clonal complexes. Combined spoligotyping and 24 loci-MIRU-VNTR revealed 47 genotypic patterns with clustering rate of 63%. Ninety five percent of LAM strains belonged to RD-Rio sub-lineage. The high clustering rate suggested that a large proportion of MDR-TB was due to recent transmission rather than independent acquisition of MDR. This spread was attributed to clonal expansion of SIT21/CAS1-Kili and SIT20/LAM1 strains. Therefore, TB control programs recommending genotyping coupled with conventional epidemiological methods can guide measures for stopping the spread of MDR-TB.

Table 2. Table showing spoligotype-based diversity of the 85 strains under the study

| Lineage | Sub-family | SIT | Number of strains | SIT (%) | Clade cumulative (%) |
|----------------|-------------------|------------|----------------------------------|----------------|-----------------------------|
| L3 | CAS1-Kili | 21 | 25 | 29 | 29 |
| | LAM1 | 20 | 12 | 14 | |
| | LAM9 | 42 | 2 | 2 | |
| | | 59 | 16 | 19 | 48 |
| | LAM11_ZWE | 815 | 9 | 11 | |
| L4 | Orphan | | 2 | 2 | |
| | H1 | Orphan | 2 | 2 | 2 |
| | T1 | 53 | 8 | 9 | |
| | T2 | 52 | 3 | 4 | 14 |
| | T2 | 317 | 1 | 1 | |
| | X2 | 137 | 5 | 6 | 6 |

Table 3. MIRU-VNTR discriminatory powers for 9, 15, and 24 loci on predominant clades in our study

| Clade | Identified patterns | | | | | Clustering rate | | | | | Cumulative HGDI | | | | | |
|--------------|----------------------------|----------------|----|----|----|------------------------|----------------|----|----|----|------------------------|----------------|-------|-------|-------|-------|
| | a | MIRU-VNTR loci | | | b | a | MIRU-VNTR loci | | | b | a | MIRU-VNTR loci | | | b | |
| | | 9 | 15 | 24 | | | 9 | 15 | 24 | | | 9 | 15 | 24 | | |
| 21/CAS1_Kili | 25 | 1 | 8 | 9 | 10 | 10 | 100 | 80 | 76 | 76 | 76 | 0 | 0.727 | 0.743 | 0.833 | 0.833 |
| 59/LAM11_ZWE | 15 | 1 | 9 | 9 | 9 | 9 | 100 | 67 | 67 | 67 | 67 | 0 | 0.914 | 0.914 | 0.914 | 0.914 |
| 20/LAM1 | 12 | 1 | 4 | 5 | 5 | 5 | 100 | 83 | 75 | 75 | 75 | 0 | 0.561 | 0.667 | 0.667 | 0.667 |

a spoligotyping

b 24 MIRU-VNTR loci + spoligotyping

Table 4. Allelic diversity for each of the 24 loci MIRU-VNTR for 87 MDR-TB isolates

| Locus | Alias | Number of tandem repeats | | | | | | | | | | | HGDI | Designation | | |
|-------|---------|--------------------------|----|----|----|----|----|----|----|----|---|----|-----------------|-------------|-----------------|------|
| | | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | | | ND ^a | |
| 4052 | QUB26 | | | 4 | 5 | 8 | 26 | 4 | 17 | 17 | | | 2 | 0.81 | High | |
| b | QUB11a | | | 6 | 12 | 26 | | 5 | | | | | 25 | 9 | 0.78 | High |
| 1644 | MIRU16 | 27 | 13 | 20 | 20 | | | | 3 | | | | | | 0.76 | High |
| 960 | MIRU10 | | 1 | 30 | 21 | 3 | 4 | 24 | | | | | | | 0.73 | High |
| 2531 | MIRU23 | | 7 | | | 30 | 34 | 12 | | | | | | | 0.68 | High |
| 2996 | MIRU26 | 25 | | 2 | 4 | 40 | 12 | | | | | | | | 0.66 | High |
| 2165 | ETR-A | | 40 | 15 | 4 | | | | | | | | 24 ^c | 0.66 | High | |
| 3192 | MIRU31 | | 11 | 39 | 28 | 4 | | | | | | | 1 | 0.65 | High | |
| 2163 | QUB11b | 2 | 44 | 13 | 21 | 3 | | | | | | | | 0.64 | High | |
| 4156 | QUB4156 | | 47 | 9 | 22 | | | | | | | | 5 | 0.60 | High | |
| 3007 | MIRU27 | 2 | 36 | 40 | 5 | | | | | | | | | 0.58 | Moderate | |
| 2401 | Mtub30 | 40 | 36 | | 7 | | | | | | | | | 0.58 | Moderate | |
| 802 | MIRU40 | 45 | | 6 | 31 | 1 | | | | | | | | 0.57 | Moderate | |
| 3690 | Mtub39 | | 52 | 22 | | 7 | 2 | | | | | | | 0.54 | Moderate | |
| 424 | Mtub04 | | 15 | 9 | 57 | 2 | | | | | | | | 0.49 | Moderate | |
| 577 | ETR-C | | 20 | 2 | 57 | 4 | | | | | | | | 0.47 | Moderate | |
| b | ETR-F | | 29 | 54 | | | | | | | | | | 0.46 | Moderate | |
| 4348 | MIRU39 | | 56 | 27 | | | | | | | | | | 0.44 | Moderate | |
| 2461 | ETR-B | 26 | 57 | | | | | | | | | | | 0.44 | Moderate | |
| 1955 | Mtub21 | | 17 | 66 | | | | | | | | | | 0.33 | Moderate | |
| 154 | MIRU02 | 2 | 81 | | | | | | | | | | | 0.05 | Poor | |
| 2687 | MIRU24 | 83 | | | | | | | | | | | | 0.0 | Poor | |
| 580 | MIRU04 | | 83 | | | | | | | | | | | 0.0 | Poor | |
| 2059 | MIRU20 | | 87 | | | | | | | | | | | 0.0 | Poor | |

^a ND-not defined: no band after gel electrophoresis

^b -non-standard 24 Loci by Supply et al. 2006

^c ETR-A failed to amplify 96 % isolates of SIT 21/CAS1-Kili

Table 5. Cumulative discriminatory index for 24-MIRU-VNTR loci and combined with spoligotyping.

| ^a Number | Loci | Alias | Number of patterns | Number of clusters | Cluster size | No. of strains clustered | CR ^b (%) | HGDI | ^c HGDI |
|---|-------------|----------------|--------------------|--------------------|--------------|--------------------------|---------------------|--------------|-------------------|
| 1 | 4052 | QUB26 | 8 | 8 | 4-26 | 83 | 100 | 0.81 | 0.810 |
| 2 | d | QUB11a | 13 | 10 | 2-25 | 80 | 96 | 0.78 | 0.856 |
| 3 | 1644 | MIRU16 | 20 | 12 | 2-20 | 75 | 90 | 0.76 | 0.900 |
| 4 | 960 | MIRU10 | 27 | 16 | 2-19 | 72 | 87 | 0.73 | 0.922 |
| 5 | 2531 | MIRU 23 | 28 | 18 | 2-13 | 73 | 88 | 0.68 | 0.945 |
| 6 | 2996 | MIRU26 | 30 | 17 | 2-13 | 70 | 84 | 0.66 | 0.945 |
| 7 | 2165 | ETR-A | 30 | 17 | 2-13 | 70 | 84 | 0.66 | 0.945 |
| 8 | 3192 | MIRU31 | 35 | 15 | 2-12 | 63 | 76 | 0.65 | 0.952 |
| ^e 9 | 2163 | QUB11b | 40 | 15 | 2-12 | 58 | 70 | 0.64 | 0.959 |
| 10 | 4156 | QUB4156 | 40 | 15 | 2-12 | 58 | 70 | 0.60 | 0.959 |
| 11 | 3007 | MIRU 27 | 41 | 16 | 2-12 | 57 | 69 | 0.58 | 0.959 |
| 12 | 2401 | Mtub30 | 41 | 16 | 2-12 | 57 | 69 | 0.58 | 0.959 |
| 13 | 802 | MIRU40 | 42 | 16 | 2-12 | 56 | 67 | 0.57 | 0.961 |
| 14 | 3690 | Mtub39 | 43 | 15 | 2-12 | 55 | 66 | 0.54 | 0.961 |
| ^e 15 | 424 | Mtu04 | 46 | 15 | 2-12 | 52 | 63 | 0.49 | 0.965 |
| 16 | 577 | ETR-C | 47 | 16 | 2-9 | 52 | 63 | 0.47 | 0.973 |
| 17 | d | ETR-F | 47 | 16 | 2-9 | 52 | 63 | 0.46 | 0.973 |
| 18 | 4348 | MIRU 39 | 47 | 16 | 2-9 | 52 | 63 | 0.44 | 0.973 |
| 19 | 2461 | ETR-B | 47 | 16 | 2-9 | 52 | 63 | 0.44 | 0.973 |
| 20 | 1955 | Mtub21 | 47 | 16 | 2-9 | 52 | 63 | 0.33 | 0.973 |
| 21 | 154 | MIRU 02 | 47 | 16 | 2-9 | 52 | 63 | 0.05 | 0.973 |
| 22 | 2687 | MIRU 24 | 47 | 16 | 2-9 | 52 | 63 | 0.0 | 0.973 |
| 23 | 580 | MIRU04 | 47 | 16 | 2-9 | 52 | 63 | 0.0 | 0.973 |
| ^e 24 | 2059 | MIRU 20 | 47 | 16 | 2-9 | 52 | 63 | 0.0 | 0.973 |
| ^e 24 loci plus spoligotyping | | | 47 | 16 | 2-9 | 52 | 63 | 0.974 | 0.973 |

^aThe columns represent the following: Number is the cumulative number of loci used. Loci/Alias represents names of the individual MIRU-VNTR locus. Number of patterns, clusters and cHGDI columns show the increase of these parameters with the addition of each MIRU-VNTR locus. Cluster size, number of clustered strains and clustering rate columns show the reduction of these parameters with the addition of each MIRU-VNTR locus. While HGDI column represents the individual HGDI of each locus starting with the locus with the highest discriminatory power.

^b Clustering rate

^c cHGDI-cumulative Hunter-Gaston discriminatory index

d -non-standard 24 Loci by Supply et al., 2006

^e Bold indicate results for cumulative 9, 15, 24, and 24 MIRU-VNTR loci plus spoligotyping




Figure 8. Map showing regions (in green) referring patients and samples to the University Teaching Hospital in Lusaka, Zambia. The regions (yellow) refer patients to Ndola Central Hospital.



Figure 9. Dendrogram based on 24 loci MIRU-VNTR and spoligotyping patterns constructed by (UPGMA). pDST and gDST = phenotypic and genotypic drug susceptibility.





Figure 10. Minimum spanning tree constructed using 24-loci MIRU-VNTR profile. Strains with single-locus differences were grouped in 7 clonal complexes. Line thickness indicates loci differences. The variations in size and partitions in each node correspond to the number of strains. Figures on the nodes are SIT numbers.



(Chihota et al., 2012; Katale et al., 2020; Namburete et al., 2020; Sagonda et al., 2014)

Figure 11. Figure showing the distribution of MDR *M. tuberculosis* strains according to sub-lineages in Zambia and its neighboring countries. The countries in white implies that the data was not captured or was not adequate.




Figure 13. Dendrogram showing 24-MIRU-VNTR and spoligotyping patterns. The order of 24-MIRU-VNTR from left to right: MIRU02, MIRU04, MIRU10, MIRU16, MIRU20, MIRU23, MIRU24, MIRU26, MIRU27, MIRU31, MIRU39, MIRU40, ETR-A, ETR-B, ETR-C, ETR-F, Mtub04, Mtub21, Mtub30, Mtub39, QUB11a, QUB11b, QUB26, and QUB4156. RD represents RD-Rio sublineage.

CHAPTER 2

Whole-genome sequencing reveals recent transmission of multidrug-resistant *Mycobacterium tuberculosis* Lineage 3 CAS1-Kili strains in Lusaka, Zambia

Introduction

Worldwide, close to 4000 lives in a day are lost due to tuberculosis (TB). In Zambia, like many other developing countries, TB is the leading cause of death especially among people living with HIV/AIDS (UNAIDS, 2018).

Mycobacterium tuberculosis, the cause of TB has seven major human-adapted lineages. One of these is lineage 3 (L3) which is predominant in East Africa, the Middle East, and South Asia (Chihota et al., 2018; O'Neill et al., 2019). Central Asian Strain 1- Kili (CAS1-Kili) forms part of lineage 3 sub-clades and is more prevalent in the eastern part of Africa (Chihota et al., 2018; Gagneux et al., 2006) (Figure 14).

Molecular epidemiological methods such as MIRU-VNTR, spoligotyping, and IS6110-RFLP have been applied to understand *M. tuberculosis* transmission based on genotypic clustering (Easterbrook et al., 2004; Hamblion et al., 2016; Xu et al., 2018). Nevertheless, these genotypic methods though targeting polymorphic sites, only interrogate one percent of the *M. tuberculosis* genome and have limited discriminatory power (Coll I Cerezo, 2015; Luo et al., 2014; Roetzer et al., 2013). Therefore, WGS provides an ultimate method for high resolution of strain relatedness and investigation of recent transmission (Walker et al., 2013). Further, it explores more drug-resistant mutations that occur outside the targeted regions by PCR-based assays (Feliciano et al., 2018). Recently, WGS has become affordable, though it is still a very big challenge for developing nations. Based on WGS results, though not yet standardized, many reports have described strains belonging to a cluster and been involved in a recent transmission event when they differ by twelve or fewer SNPs and five or fewer SNPs respectively in their core genomes (Lalor et al., 2018; Walker et al., 2013).

Previously we reported a relatively higher percentage of lineage 3 Spoligotype International Types (SIT) 21/CAS1-Kili strains among multi-drug resistant (MDR) *M. tuberculosis* strains in Zambia when compared to other southern African countries (Chizimu et al., 2021). Despite its low proportions in the region when compared to predominant lineage 4, lineage 3 strains (SIT21/CAS1-Kili) were associated with MDR TB and implicated for its

spread in Lusaka, Zambia (Solo et al. 2021; Chizimu et al. 2021). Among the studied MDR *M. tuberculosis* strains, 24-loci MIRU-VNTR and spoligotyping showed clonal expansion of the SIT21/CAS1-Kili strains (Chizimu et al., 2021). The findings in those studies supported the possibility of recent transmission though this could not be concluded due to the limitations of the used genotyping methods in discriminating between closely related strains. Thus, this study aims to investigate recent transmission among the MDR *M. tuberculosis* SIT21/CAS1-Kili strains in Lusaka, Zambia, by WGS.

Materials and Methods

Study samples

I used strains from the previous study conducted in Lusaka from 2013 to 2017 (Chizimu et al., 2021). In the previous study, 87 MDR-TB strains were typed by spoligotyping and 24-loci MIRU-VNTR, of which 25 CAS1-Kili strains formed the largest clonal cluster and were suspected to represent a recent transmission event (Chizimu et al., 2021). All CAS1-Kili strains were considered for WGS though only 13 were successfully sequenced. The other 12 strains had poor DNA quality, hence excluded from the current study.

Culturing and drug susceptibility testing

Briefly, sub-culturing of the isolates was done in BACTEC™ 960 MGIT™ (Mycobacteria Growth Indicator Tube) system (Becton Dickson & Co., Franklin Lakes, NJ, USA) following the manufacturer's instructions. The critical concentrations for isoniazid, rifampicin, streptomycin, and ethambutol, as prescribed by the kit manufacturer (Becton, Dickinson, and Company), of 0.1, 1.0, 1.0, and 5.0 g/mL were used, respectively.

DNA extraction and genotyping

DNA was extracted by heating method as described previously (Chizimu et al., 2021; Solo et al., 2021). The extracted DNA was transported to the Hokkaido University International Institute for Zoonosis Control, Japan for analysis. Further, 24-loci MIRU-VNTR (Supply et al., 2006) and spoligotyping (Kamerbeek et al., 1997) were performed as previously described (Chizimu et al. 2021; Solo et al. 2021).

Whole-genome sequencing analysis

Library preparations were performed following Nextera XT DNA Library Preparation Kit (Illumina Inc., San Diego, CA, USA) manufacturer's instructions, and Illumina MiSeq 2500 platform was used for sequencing. WGS data analysis was carried out as previously described (Batut et al., 2018; Heusden et al., 2021). The raw paired reads were checked for quality using fastqc, results compiled using multiQC (Ewels et al., 2016). Trimmomatic was

used to trim adapters, low-quality bases and filtering for a minimum read length of 20 (SLIDINGWINDOW:4:20 MINLEN:20) (Bolger et al., 2014). Variants were called using Snippy pipeline (Seemann. T, 2020); briefly, reads were aligned to the reference strain H37Rv (NC_000962.3) by Burrows Wheel Aligner (BWA), manipulated with SAMtools, and variant calling with freebayes, while variant annotation was performed with SnpEff. Further, Snippy-core generated full and core genome alignments. Gubbins (Croucher et al., 2014) was further used to generate filtered polymorphic sites.

Therefore, filtered SNPs in variable and invariable sites were used to calculate a pairwise distance matrix and maximum likelihood phylogenetic tree using RAxMLv8.2.11 in Geneious v 10.2.6, Biomatters, Ltd., Auckland, New Zealand <https://www.geneious.com> (accessed on Dec 16, 2021). The mean coverages of the analyzed reads for 12 CAS1-Kili strains ranged from 35.73 to 139.32 (Table 6). One strain (strain 02) was excluded due to poor coverage. Resistance patterns and sub-lineages were determined by TB Profiler (Coll et al., 2015; Phelan et al., 2019) and PhyResSE (Feuerriegel et al., 2015). We further manually confirmed the variants using CLC Genomics workbench 10 (QIAGEN, Hilden, Germany) (CLC Genomics Workbench, 2013). To understand the likely pattern of drug-resistant mutations acquisition by the strains, the drug-resistant mutations were conveniently plotted on the phylogenetic tree.

Phylogenetic assessment of global sub-lineage CAS1-Kili (L3.1.1)

Sub-lineage 3.1.1 strain's accession numbers were obtained from TB-Profiler, projects PRJEB29435 (Katale et al., 2020) and PRJEB33896 (Shuaib et al., 2020). A total of 527 pairs of raw reads were downloaded from the ENA browser and 480 of these were successfully analyzed. All raw reads were processed as described above. Additionally, to avoid false hits in the repetitive regions, SNPs in Proline-glutamate (PE) or proline-proline-glutamate (PPE) gene families were filtered by *M. tuberculosis* BED mask file included in Snippy-package. Further, Gubbins generated filtered polymorphic sites and a maximum likelihood phylogenetic tree rooted to *M. canetti*. The phylogenetic tree was trimmed of *M. canetti* but topology maintained, for better visualization using ggtree (Team, 2020; Yu, 2020; Yu et al., 2018, 2017). To confirm the sub-lineage and drug resistance patterns for some strains, TB-Profiler was used. Further, SNP distances using Ape package (Paradis E, Claude J, 2004) and Wilcoxon signed-rank test were calculated in R-studio (Team, 2020). Only countries with more than 10 strains were considered for SNP distance calculation.

Results

Cluster analysis

Among our Zambian strains, 11/12 (92%) differed by not more than 12 SNPs, while 6 (50%) strains differed with at least one other strain by 5 or fewer SNPs. Strain 7 was closely related to strains 4, 5, and 11. Additionally, strain 7 had the lowest average SNP difference of 9 SNPs to other strains, as shown in Table 7. On the contrary, strain 6 had the highest average SNP difference of 23 SNPs to the other strains.

Resistance patterns and Phylogeny

All strains had the same mutations for isoniazid resistance (KatG, Ser 315 Thr). With the exception of one strain with EmbB Met 306 Leu (Strain 6, Figure 15), 92% (11/12) had the same mutation associated with ethambutol resistance (Met 306 Ile) though only 25% (3/12) had the corresponding phenotypic resistance, as shown in Figure 15. Among 11 EmbB Met 306 Ile mutants, 36% (4/11) strains had additional mutations in *embA*, and three of these were phenotypically resistant to ethambutol. Additionally, all the 12 strains had resistance-associated mutations to streptomycin. Of these twelve strains, four and one had mutations in *rpsL* and *rrs* genes, respectively, and all were resistant to streptomycin, while 7/12 had mutations in *gid* and only two out of those seven were resistant to streptomycin. Overall, strains had different mutations towards rifampicin resistance while all RpoB Ser 450 Leu mutants had compensatory mutations in RpoC Val 483 (Figure 16). Among four strains having RpoB Asp 435 deletion, three had a mutation in RpoB Thr 1047 Ile and one had that in RpoC Trp 105 Arg. The strains seemed to have accumulated drug-resistance-associated mutations in a stepwise pattern (Figure 15). One strain (strain 3) had both -16 C > T and -16 C > G nucleotide variants in the *embA* gene. Strains having the same mutations for drug resistance to several drugs had a correspondingly small number of SNP differences between them (Table 7, Figures 15 and 16).

Phylogenetic assessment of global sub-lineage CAS1-Kili (L3.1.1)

Most of the lineage 3.1.1 (SIT21/CAS1-Kili) strains were from Europe, 52% (250/480), followed by Africa, 48% (228/480) (Table 8). Zambian strains formed a monophyletic clade,

closer to Malawian strains but both descending from the Tanzanian strains (Figure 17a and b). The clade having the Zambian strains also had strains from the United Kingdom (Figure 17b). The majority of the global strains were pan-susceptible (78%, 375/480), while 13% (60/480) were MDR and 2% (9/480) were resistant to other anti-tuberculosis drugs (Figures 17a and 19). Moreover, Zambian strains had the lowest median SNP distance when compared to strains from other countries ($p < 0.000$) (Figure 18).

Discussion

The SIT21/CAS1-Kili *M. tuberculosis* strains were previously shown to be associated with the clonal spread of MDR-TB in the Lusaka District (Chizimu et al., 2021; Solo et al., 2021). In this study, we applied WGS to investigate recent transmission events among SIT21/CAS1-Kili strains that was suggested by the combination of 24-MIRU-VNTR loci and spoligotyping. Of the 12 evaluated SIT21/CAS1-Kili strains, 11 belonged to a cluster, as they differed by 12 or fewer SNPs in their core genomes, while 6 strains were involved in recent transmission events as they differed by ≤ 5 SNPs to at least one other strain. Therefore, WGS revealed that the SIT21/CAS1-Kili strains were closely related as they exhibited comparatively low variabilities in SNPs. In addition, several strains shared the same combinations of drug-resistance-associated mutations to isoniazid, ethambutol, rifampicin, and other anti-TB drugs. This provided more evidence on the clonal spread of MDR SIT21/CAS1-Kili strains in this region, calling for interventions to stop this possible outbreak.

Despite some reports indicating the reduced fitness as a result of drug resistance evolution (Andersson, 2006; Asare et al., 2020), others have indicated emanating high fitness strains with preserved ability to spread (Leung et al., 2013; Metcalfe et al., 2010). Thus, the latter might explain the scenario in our current study. In addition, 75% (9/12) of strains had additional mutations besides the major resistance-associated mutations to rifampicin in *rpoB*, of which 33% (4/12) of strains with RpoB Ser 450 Leu mutation also had compensatory mutations in RpoC, Val 483 Ala (2/4) and Val 483 Gly (2/4). These compensatory mutations have been implicated in mitigating the fitness defects caused by RpoB Ser450Leu substitution in *M. tuberculosis* (Comas et al., 2011) which in turn contribute to the successful spread of MDR-TB. Interestingly, other strains had novel mutations in *rpoB* (3/12, Thr 1074 Ile) and *rpoC* (1/12, Trp 105 Arg) which were suspected to be compensatory as they occurred in association with a known mutation, Asp 435 deletion (4/12), in the *rpoB* RRDR. However, this can only be confirmed by allelic exchange experiments.

Similarly, 33% (4/12) of strains had mutations in more than a single resistance-conferring gene to ethambutol. The phenomenon has been reported to be associated with high resistance to ethambutol (Bakuła et al., 2013; Li et al., 2020; Qing et al., 2021; Safi et al., 2008). In fact, all three strains which were phenotypically resistant to ethambutol in this study had multiple mutations towards ethambutol resistance. In addition, one of the three EMB-resistant strains (strain 8) had a novel mutation in the *embA* gene regulatory region (-35 A > deletion), whilst one other strain (strain 3) had -16 C > T and -16 C > G nucleotide variants in *embA*,

which was suggestive of ongoing evolution within the strain. All the 12 MDR strains had mutations in codon *embB* 306 which has been associated with isoniazid resistance (Parsons et al., 2005), MDR, and more likely to evolve to XDR-TB (Bakula et al., 2013; Hazbón et al., 2005; Safi et al., 2008).

Further, codon *embB* 306 mutations have been reported to reduce susceptibility of *M. tuberculosis* to other drugs used i. Therefore, based on this understanding, it can be speculated that possibly the strains first acquired drug resistance to isoniazid (KatG, Ser 315 Thr) and ethambutol (*EmbB* 306) then independently became resistant to other drugs, rifampicin, streptomycin, and pyrazinamide, while propagating to the next patients (Figure 15). As a result, rapid and low-cost diagnostic techniques for detecting *embB* 306 mutations in drug-resistant strains, particularly in high-burden drug-resistant TB areas, are encouraged to guide patient management and control of drug-resistant TB (Safi et al., 2008; Shen et al., 2007; Shuaib et al., 2020).

Even though some strains were resistant to all the first-line anti-TB drugs and streptomycin, none had resistance mutations to other second-line drugs. This at least left some treatment options for these patients, though on the other hand, calls for improved resistance detection and individualized treatment. The observed discrepancy in phenotypic and genotypic drug susceptibility patterns for ethambutol can be attributed to lack of consistency of phenotypic DST to ethambutol resistance determination as indicated by several reports (Hazbón et al., 2005; Leung et al., 2013).

Mutations in *embB* 306, which is associated with the majority of drug-resistant strains to ethambutol, have also been detected in susceptible strains (Shen et al., 2007), whilst the same discrepancy for streptomycin might be due to low-level resistance-conferring mutations in *gid* to the drug, which may result in susceptible phenotype (Wong et al., 2011). Mutations in *rrs* and *rpsL* genes have been associated with intermediate to high (Meier et al., 1996) and high levels of resistance to streptomycin (Bwalya et al., 2021; Meier et al., 1996; Sun et al., 2016; Wong et al., 2011), respectively. In addition, drug susceptibility testing is not routinely performed on all patients with TB, hence the treatment regimen in some cases may not be appropriate and this facilitates resistance amplification and further transmission of primary drug-resistant TB (Shuaib et al., 2020).

Phylogeny showed that some strains involved in recent transmission events were from patients residing in different districts (Monze, Chikankata) and Lusaka City (Figures 16 and 20). This conceivably suggests that there could be many unknown related intermediary cases

not captured by this study hence posing a threat for more outbreaks in the future. Therefore, this calls for more improved contact tracing strategies to curtail this transmission.

Further, some previously identical strains by MIRU-VNTR and spoligotyping were delineated as unique strains by WGS, indicating its supremacy to traditional genotyping methods (Alaridah et al., 2019; Xu et al., 2019). Though the application of WGS on TB epidemiology is still challenging in developing nations like Zambia, its combination where possible, with traditional genotyping methods, can make it cost-effective and be utilized as a supporting tool, especially for large-size population studies.

Generally, the global SIT21/CAS1-Kili (L3.1.1) strains were pan-susceptible to anti-TB drugs (Figure 17a and 19). Therefore, the outbreak of drug resistance among Zambian strains might be due to local factors such as late diagnosis, poor compliance, incomplete contact investigations, or other unknown reasons in the TB control system. Interestingly, the relationship of our Zambian strains to those from Malawi and Tanzania was suggestive of the possible origin of this strain to be Tanzania, in agreement with Chihota et al., 2018 (Chihota et al., 2018). Then, it spread to Malawi before Zambia. This finding also illustrated that the TB structure in a country is likely to be influenced by TB events in the neighboring countries in addition to local factors. Therefore, regional coordination in TB control is cardinal as movements of people for trade, migration, and refuge facilitate the spread of TB (Alyamani et al., 2019; Casper et al., 1996). SIT21/CAS1-Kili (L3.1.1) strains related to the Zambian and other African countries are also causing TB disease in European countries such as the United Kingdom, as suggested by the existence of these strains in the same clade. This spread can be attributed to the movements of people from the eastern part of Africa to Europe for economic activities and refuge (Alaridah et al., 2019; Walker et al., 2018).

The study limitations included small sample size due to poor quality DNA for some samples and inadequate patient history to precisely infer the direction for person-to-person transmission. In addition, a larger sample size with a longer collection period of the strains would have facilitated the determination of the emergency of MDR-TB and its hotspots in Lusaka. Additionally, the sample size also affected the generalization of these results. Therefore, we recommend MDR-TB surveillance on the large scale, whenever possible, to provide more information on the spread of this strain and other genotypes in the community, which can inform policy.

Conclusions

The study revealed ongoing transmission of MDR SIT21/CAS1-Kili strains in Lusaka, Zambia, which is a public health concern and needs more evaluation. It also showed the high resolution of WGS in delineating closely related strains and determining antibiotic resistance. Further, the study supports the complimentary use of WGS with traditional methods. Intensified case finding, improved drug resistance detection and adherence to treatment can help interrupt the transmission chains.

Summary

Globally, tuberculosis (TB) is a major cause of death due to antimicrobial resistance. *Mycobacterium tuberculosis* CAS1-Kili strains that belong to lineage 3 (Central Asian Strain, CAS) were previously implicated in the spread of multidrug-resistant (MDR)-TB in Lusaka, Zambia. Thus, we investigated recent transmission of those strains by whole-genome sequencing (WGS) with Illumina MiSeq platform. Twelve MDR CAS1-Kili isolates clustered by traditional methods (MIRU-VNTR and spoligotyping) were used. A total of 92% (11/12) of isolates belonged to a cluster (≤ 12 SNPs) while 50% (6/12) were involved in recent transmission events, as they differed by ≤ 5 SNPs. All the isolates had KatG Ser 315 Thr (isoniazid resistance), EmbB Met306 substitutions (ethambutol resistance) and several kinds of *rpoB* mutations (rifampicin resistance). WGS also revealed compensatory mutations including a novel deletion in *embA* regulatory region ($-35A > \text{del}$). Several strains shared the same combinations of drug-resistance-associated mutations indicating transmission of MDR strains. Zambian strains belonged to the same clade as Tanzanian, Malawian and European strains, although most of those were pan-drug-susceptible. Hence, complimentary use of WGS to traditional epidemiological methods provides an in-depth insight on transmission and drug resistance patterns which can guide targeted control measures to stop the spread of MDR-TB




Figure 14. Distribution of SIT21/CAS1-Kili strains by country. Data obtained from SITVIT2 MTBC Database (Demay et al., 2012).




Figure 15. Phylogenetic tree illustrating the relations of the studied SIT21/CAS1-Kili strains. Drug-resistance-associated mutations of each strain are represented by different shapes on the branches and highlighted as indicated by the legend. Fs in the legend stand for frameshift. A, is for phenotypic drug susceptibility patterns. Black and white circles represent results of drug-resistant and susceptible phenotypes, respectively. B, Represents drug-resistant-associated mutations. Black and white squares indicate the presence and absence of drug-resistance-associated mutations to a particular drug, respectively. CTK in the district column stands for a district Chikankata. An ‘S’ letter before each ID number stands for strain. In the legend, RIF, INH, STR, EMB and PZA stand for rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide, respectively.




Figure 16. Nucleotide changes in drug resistance associated genes and number of strains having the same nucleotide change among the 13 SIT21/CAS1-Kili strains. The strain IDs are arranged in relation to Figure 15 (Starting from the top). Fs in the figure represents frameshift.





Figure 17. (a). Phylogenetic tree for global L3.1.1 strains. The countries are represented by small circles on the tips of the tree and colored as shown in the legend. The inner (R) and outer circles (C) were colored according to the drug resistance patterns and regions of strain isolation (as continents), respectively. (b). Enlargement of the clade containing the Zambian strains.




Figure 18. Comparison of median SNP distances of global representative L3.1.1 strains by country to Zambian strains. The differences in median SNP distance were significant ($p < 0.000$). Only countries with more than 10 strains were considered.




Figure 19. Phylogenetic tree with detailed drug resistant mutations for each global L3.1.1 strain. R = rifampicin, I = isoniazid, P = pyrazinamide, E = ethambutol, S = streptomycin, A = drug resistance pattern, C = continent




Figure 20. Map showing the residence districts of the 12 patients highlighted in different colors. Seven patients were from Lusaka, and one from Chikankata. Monze and Kabwe had two patients each.

Table 6. Information on the 12 CAS1-Kili Zambian strains.

| Sample Number | Mean Coverage | Standard deviation | Mean read length | Total sequences | Number of reads |
|---------------|---------------|--------------------|------------------|-----------------|-----------------|
| S1 | 63.75 | ± 17.34 | 249.97 | 579110 | 1224370 |
| S3 | 139.32 | ± 39.43 | 209.31 | 1522426 | 3195791 |
| S4 | 35.73 | ± 21.40 | 260.14 | 318802 | 750634 |
| S5 | 118.74 | ± 36.57 | 178.23 | 1534056 | 3292956 |
| S6 | 46.17 | ± 15.43 | 250.57 | 426310 | 900458 |
| S7 | 111.68 | ± 27.18 | 167.49 | 1550554 | 3334987 |
| S8 | 43.29 | ± 13.69 | 254.62 | 387347 | 799903 |
| S9 | 44.75 | 16.08 | 250.83 | 415133 | 868824 |
| S10 | 73.28 | ± 20.76 | 278.31 | 604304 | 1252391 |
| S11 | 75.05 | ± 21.14 | 266.89 | 641298 | 1345606 |
| S12 | 76.3 | ± 21.52 | 271.42 | 644606 | 1347590 |
| S13 | 99.68 | ± 25.76 | 212.6 | 1066338 | 2159212 |

Table 7. Similarity matrix showing core-SNP differences of the 12 SIT21/CAS1-Kili strains. SNPs differences between strains ranged from 1 to 26 SNPs.

| | Strain ID | | | | | | | | | | | | SNP Difference ¹ | | |
|-----|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----------------------------|-----|-----|
| | S01 | S03 | S13 | S08 | S10 | S09 | S12 | S04 | S07 | S11 | S05 | S06 | ≤5 | ≤12 | ≥13 |
| S01 | | 9 | 8 | 11 | 12 | 9 | 11 | 11 | 10 | 11 | 14 | 24 | 0 | 9 | 2 |
| S03 | 9 | | 7 | 10 | 11 | 8 | 10 | 10 | 9 | 10 | 13 | 23 | 0 | 9 | 2 |
| S13 | 8 | 7 | | 9 | 10 | 7 | 9 | 9 | 8 | 9 | 12 | 22 | 0 | 10 | 1 |
| S08 | 11 | 10 | 9 | | 3 | 5 | 12 | 10 | 9 | 10 | 13 | 23 | 2 | 9 | 2 |
| S10 | 12 | 11 | 10 | 3 | | 6 | 13 | 11 | 10 | 11 | 14 | 24 | 1 | 8 | 3 |
| S09 | 9 | 8 | 7 | 5 | 6 | | 10 | 8 | 7 | 8 | 11 | 21 | 1 | 10 | 1 |
| S12 | 11 | 10 | 9 | 12 | 13 | 10 | | 12 | 11 | 12 | 15 | 25 | 0 | 8 | 3 |
| S04 | 11 | 10 | 9 | 10 | 11 | 8 | 12 | | 1 | 2 | 7 | 23 | 2 | 8 | 1 |
| S07 | 10 | 9 | 8 | 9 | 10 | 7 | 11 | 1 | | 1 | 6 | 22 | 2 | 10 | 1 |
| S11 | 11 | 10 | 9 | 10 | 11 | 8 | 12 | 2 | 1 | | 7 | 23 | 2 | 10 | 1 |
| S05 | 14 | 13 | 12 | 13 | 14 | 11 | 15 | 7 | 6 | 7 | | 26 | 0 | 5 | 6 |
| S06 | 24 | 23 | 22 | 23 | 24 | 21 | 25 | 23 | 22 | 23 | 26 | | 0 | 0 | 11 |

Legend: ≤ 5 SNPs; ≤ 12 SNPs; ≥ 13 SNPs. ¹ Number of strains differing by ≤5, ≤12, and ≥13 SNPs to an individual strain. The letter S before the ID stands for strain. Boxes are highlighted according to the SNP differences as shown in the legend.

Table 8. Number of L3.1.1 global strains from each country.

| Country | Susceptible | Pre-MDR | MDR | Others | Total |
|----------------|--------------------|----------------|------------|---------------|--------------|
| Canada | 5 | | | | 5 |
| United Kingdom | 48 | 1 | 1 | 1 | 51 |
| Finland | 3 | | 1 | | 4 |
| Norway | 69 | 8 | 3 | 6 | 86 |
| Netherlands | 88 | 5 | 6 | | 99 |
| Sweden | 1 | | 4 | | 5 |
| Saudi Arabia | 2 | | | | 2 |
| Djibouti | 5 | 2 | 5 | | 12 |
| Uganda | 1 | 1 | 2 | | 4 |
| Malawi | 119 | 15 | | | 134 |
| Tanzania | 16 | 3 | 17 | | 36 |
| Zambia | | | 12 | | 12 |
| South Africa | 12 | 1 | 9 | 1 | 23 |
| Sudan | 6 | | | 1 | 7 |
| Total | 375 | 36 | 60 | 9 | 480 |

Table 9. List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler.

| accession No. | Drug resistance | Sublineage | Continent | Country | Drug resistance mutations | | | | |
|---------------|-----------------|------------|---------------|----------------|---------------------------|-----------|-------------|-----------|----------|
| | | | | | RIF | INH | PRZ | EMB | STM |
| SRR6397767 | Sensitive | L3.1.1 | North_America | Canada | - | - | - | - | - |
| SRR6152824 | Sensitive | L3.1.1 | North_America | Canada | - | - | - | - | - |
| SRR6153047 | Sensitive | L3.1.1 | North_America | Canada | - | - | - | - | - |
| SRR6397490 | Sensitive | L3.1.1 | North_America | Canada | - | - | - | - | - |
| SRR6397545 | Sensitive | L3.1.1 | North_America | Canada | - | - | - | - | - |
| SRR5818587 | MDR | L3.1.1 | Africa | Djibouti | Ser450Leu | Ser315Thr | - | Met306Ile | - |
| SRR5818617 | MDR | L3.1.1 | Africa | Djibouti | Ser450Leu | Ser315Thr | - | multiple | multiple |
| SRR5818618 | Pre-MDR | L3.1.1 | Africa | Djibouti | His445Tyr | - | - | - | - |
| SRR5818620 | MDR | L3.1.1 | Africa | Djibouti | Ser450Leu | Ser315Thr | - | Met306Ile | multiple |
| SRR5818636 | MDR | L3.1.1 | Africa | Djibouti | Ser450Leu | Ser315Thr | - | multiple | multiple |
| SRR5818637 | MDR | L3.1.1 | Africa | Djibouti | - | - | - | - | - |
| SRR5818704 | Pre-MDR | L3.1.1 | Africa | Djibouti | - | - | - | - | - |
| SRR5818578 | Sensitive | L3.1.1 | Africa | Djibouti | - | - | - | - | - |
| SRR5818585 | Sensitive | L3.1.1 | Africa | Djibouti | - | - | - | - | - |
| SRR5818607 | Sensitive | L3.1.1 | Africa | Djibouti | - | - | - | - | - |
| SRR5818683 | Sensitive | L3.1.1 | Africa | Djibouti | - | - | - | - | - |
| SRR5818689 | Sensitive | L3.1.1 | Africa | Djibouti | - | - | - | - | - |
| ERR1200630 | Sensitive | L3.1.1 | Africa | Ethiopia | - | - | - | - | - |
| ERR2503423 | MDR | L3.1.1 | Europe | Finland | - | - | - | - | - |
| ERR2503494 | Sensitive | L3.1.1 | Europe | Finland | - | - | - | - | - |
| ERR2503469 | Sensitive | L3.1.1 | Europe | Finland | - | - | - | - | - |
| ERR2503524 | Sensitive | L3.1.1 | Europe | Finland | - | - | - | - | - |
| ERR046968 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046969 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046970 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046982 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046983 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR400465 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR2516860 | Pre-MDR | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR2516908 | MDR | L3.1.1 | Europe | United_Kingdom | Ser450Leu | multiple | 192_193insA | Met306Val | Lys88Arg |
| ERR025834 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038264 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038265 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038266 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038269 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038270 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038271 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038272 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038273 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038298 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038299 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR038300 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR039323 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040086 | Other | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040087 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040088 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040090 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040091 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040093 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040106 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040107 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR040108 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046729 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046769 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046770 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046771 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046772 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046775 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046845 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046847 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046854 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046857 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046858 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046860 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046861 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046866 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046867 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046914 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046921 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046936 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046940 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR046942 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |

Table 9: List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler continues.....

| Accession No. | Drug resistance | Sublineage | Continent | Country | Drug resistance mutations | | | | |
|---------------|-----------------|------------|-----------|----------------|---------------------------|-------------|-----|-----|-----|
| | | | | | RIF | INH | PRZ | EMB | STM |
| ERR046965 | Sensitive | L3.1.1 | Europe | United_Kingdom | - | - | - | - | - |
| ERR190347 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR212146 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR245757 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR245777 | Pre-MDR | L3.1.1 | Africa | Malawi | - | fabG1_c.-1- | - | - | - |
| ERR245792 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR245805 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR036193 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR036210 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR036216 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245832 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR037502 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161040 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245838 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR161064 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161065 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245646 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245668 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245671 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245676 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245684 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245687 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245688 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245689 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245694 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245702 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245704 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245713 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245715 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245726 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245732 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245766 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245768 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245789 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245796 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245803 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245827 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245839 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR245840 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR036218 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161083 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161099 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161107 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161167 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161198 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161199 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161200 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR163939 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR163951 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR163966 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR163973 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR163978 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176455 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176466 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181692 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR176471 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176479 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176481 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176497 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176504 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176528 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176577 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176600 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176601 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176603 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176648 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176657 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176662 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176668 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176670 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176674 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176704 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |

Table 9: List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler continues.....

| Accession No. | Drug resistance | Sublineage | Continent | Country | Drug resistance mutations | | | | |
|---------------|-----------------|------------|-----------|-------------|---------------------------|-----------|-----|-----|-----|
| | | | | | RIF | INH | PRZ | EMB | STM |
| ERR176731 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR176791 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181683 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181707 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181713 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181715 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181717 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181718 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181736 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181763 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR181770 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181790 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181800 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181802 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181804 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181812 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181817 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181830 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181842 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181846 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181851 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181854 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181856 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181863 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181883 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181892 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181906 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181953 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181970 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181994 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR182044 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR190341 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR190357 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR190372 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR190404 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR190407 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR190408 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR211997 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR212007 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR212026 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR212027 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR212029 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR212031 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR212142 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR212147 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR216937 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR216981 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR221576 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR221587 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR221591 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR036243 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR037492 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181763 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR161079 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161082 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161169 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR161192 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR163974 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181808 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR164011 | Sensitive | L3.1.1 | Africa | Malawi | - | - | - | - | - |
| ERR181815 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR181852 | Pre-MDR | L3.1.1 | Africa | Malawi | His445Asp | - | - | - | - |
| ERR212017 | Pre-MDR | L3.1.1 | Africa | Malawi | - | Ser315Thr | - | - | - |
| ERR2446176 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446296 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446308 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446364 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446372 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446390 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446430 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446437 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446467 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446511 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |

Table 9: List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler continues.....

| Accession No. | Drug resistance | Sublineage | Continent | Country | Drug resistance mutations | | | | |
|---------------|-----------------|------------|-----------|-------------|---------------------------|-----------|-------------|-----------|----------|
| | | | | | RIF | INH | PRZ | EMB | STM |
| ERR2446524 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446565 | Pre-MDR | L3.1.1 | Europe | Netherlands | - | Ser315Thr | - | - | - |
| ERR2446580 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275191 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275214 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275217 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275218 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | _102del |
| ERR3275229 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275314 | Pre-MDR | L3.1.1 | Europe | Netherlands | - | Ser315Thr | - | - | - |
| ERR3275320 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275321 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275402 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275405 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275443 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275456 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275470 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275481 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275520 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275574 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275614 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275616 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275643 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275686 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275704 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275708 | Pre-MDR | L3.1.1 | Europe | Netherlands | - | Ser315Thr | - | - | - |
| ERR3275711 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275718 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275737 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275744 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275761 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275764 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275766 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275770 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275822 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275825 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275841 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275842 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275870 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275877 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275904 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275908 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275932 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275943 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3275962 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276012 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276018 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276049 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276059 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276070 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276125 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276143 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276159 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276183 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276197 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276211 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276230 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276270 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR3276291 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446105 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2446116 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | multiple |
| ERR2446234 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2516466 | Pre-MDR | L3.1.1 | Europe | Netherlands | Ser450Leu | - | - | - | - |
| ERR2516567 | MDR | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2516594 | MDR | L3.1.1 | Europe | Netherlands | His445Tyr | Ser315Thr | - | - | Lys88Arg |
| ERR2516609 | MDR | L3.1.1 | Europe | Netherlands | Ser450Leu | Ser315Thr | - | - | - |
| ERR2516634 | MDR | L3.1.1 | Europe | Netherlands | Ser450Leu | Ser315Thr | 192_193insA | Met306Val | - |
| ERR2517142 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517148 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517152 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | _115del |
| ERR2517158 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | _102del |
| ERR2517188 | MDR | L3.1.1 | Europe | Netherlands | Ser450Leu | Ser315Thr | - | Met306Ile | - |
| ERR2517235 | Pre-MDR | L3.1.1 | Europe | Netherlands | - | Ser315Thr | - | - | - |
| ERR2517240 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |

Table 9: List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler continues.....

| Accession No. | Drug resistance | Sublineage | Continent | Country | Drug resistance mutations | | | | |
|---------------|-----------------|------------|-----------|-------------|---------------------------|-------------|-------------|-----------|----------|
| | | | | | RIF | INH | PRZ | EMB | STM |
| ERR2517249 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517251 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517278 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517331 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517348 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | 906a>g |
| ERR2517360 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517371 | MDR | L3.1.1 | Europe | Netherlands | Ser450Leu | Ser315Thr | Trp119Arg | Gln497Arg | - |
| ERR2517404 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517407 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517419 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517441 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517581 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | - |
| ERR2517597 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | _386del |
| ERR2517626 | Sensitive | L3.1.1 | Europe | Netherlands | - | - | - | - | multiple |
| ERR2245301 | MDR | L3.1.1 | Europe | Norway | His445Tyr | Ser315Thr | Ser164Pro | Met306Val | Lys88Arg |
| ERR2245391 | MDR | L3.1.1 | Europe | Norway | multiple | Ser315Thr | Ala102Thr | Met306Val | Lys43Arg |
| ERR2245421 | MDR | L3.1.1 | Europe | Norway | Ser450Leu | Ser315Thr | 192_193insA | Met306Val | Lys43Arg |
| ERR2245337 | Other | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245338 | Other | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245340 | Other | L3.1.1 | Europe | Norway | - | - | - | - | Lys43Arg |
| ERR2245375 | Other | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245378 | Other | L3.1.1 | Europe | Norway | - | - | - | - | _351del |
| ERR2245396 | Other | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245296 | Pre-MDR | L3.1.1 | Europe | Norway | Ser450Leu | - | - | - | - |
| ERR2245305 | Pre-MDR | L3.1.1 | Europe | Norway | - | fabG1_c.-1- | - | - | - |
| ERR2245342 | Pre-MDR | L3.1.1 | Europe | Norway | - | - | - | - | _102del |
| ERR2245346 | Pre-MDR | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245363 | Pre-MDR | L3.1.1 | Europe | Norway | - | fabG1_c.-1- | - | - | _351del |
| ERR2245365 | Pre-MDR | L3.1.1 | Europe | Norway | - | Ser315Thr | - | - | _102del |
| ERR2245409 | Pre-MDR | L3.1.1 | Europe | Norway | - | Ser315Thr | - | Met306Ile | - |
| ERR2245416 | Pre-MDR | L3.1.1 | Europe | Norway | - | Ser315Thr | - | - | - |
| ERR2245279 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245284 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245285 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245287 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245288 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245289 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245290 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245292 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245294 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245295 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245297 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245298 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245299 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245300 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245303 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245306 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245333 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245335 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245336 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245341 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245353 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245356 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245364 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245366 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245367 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245372 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245373 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245374 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245376 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245377 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245379 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245380 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245381 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245382 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245383 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245384 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245385 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245386 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245388 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245389 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245390 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245392 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |

Table 9: List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler continues.....

| Accession No. | Drug resistance | Sublineage | Continent | Country | Drug resistance mutations | | | | |
|---------------|-----------------|------------|-------------|--------------|---------------------------|-----------|--------------|---------------|----------|
| | | | | | RIF | INH | PRZ | EMB | STM |
| ERR2245393 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245395 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245397 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245398 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245399 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245401 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245402 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245403 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245406 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245407 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245408 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245410 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245411 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245412 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245413 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245414 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245415 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245417 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245418 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245419 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245420 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245422 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245423 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245424 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2245427 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2512376 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR2512378 | Sensitive | L3.1.1 | Europe | Norway | - | - | - | - | - |
| ERR1035167 | Sensitive | L3.1.1 | Middle_East | Saudi_Arabia | - | - | - | - | - |
| ERR1035172 | Sensitive | L3.1.1 | Middle_East | Saudi_Arabia | - | - | - | - | - |
| ERR3470579 | Sensitive | L3.1.1 | Africa | Sudan | - | - | - | - | - |
| ERR3470580 | Sensitive | L3.1.1 | Africa | Sudan | - | - | - | - | - |
| ERR3470573 | Sensitive | L3.1.1 | Africa | Sudan | - | - | - | - | - |
| ERR3470620 | Sensitive | L3.1.1 | Africa | Sudan | - | - | - | - | - |
| ERR3470613 | Other | L3.1.1 | Africa | Sudan | - | - | - | - | - |
| ERR3470556 | Sensitive | L3.1.1 | Africa | Sudan | - | - | - | - | Lys43Arg |
| ERR3470623 | Sensitive | L3.1.1 | Africa | Sudan | - | - | - | - | Lys43Arg |
| strain_01 | MDR | L3.1.1 | Africa | Zambia | His445Asp | Ser315Thr | - | Met306Ile | _115del |
| strain_03 | MDR | L3.1.1 | Africa | Zambia | multiple | Ser315Thr | 380_388del | multiple | _115del |
| strain_04 | MDR | L3.1.1 | Africa | Zambia | - | Ser315Thr | Met175Val | multiple | _102del |
| strain_05 | MDR | L3.1.1 | Africa | Zambia | - | Ser315Thr | Met175Val | Met306Ile | multiple |
| strain_06 | MDR | L3.1.1 | Africa | Zambia | His445Asp | Ser315Thr | - | Met306Leu | _351del |
| strain_07 | MDR | L3.1.1 | Africa | Zambia | - | Ser315Thr | Met175Val | Met306Ile | _351del |
| strain_08 | MDR | L3.1.1 | Africa | Zambia | Ser450Leu | Ser315Thr | - | Met306Ile | - |
| strain_09 | MDR | L3.1.1 | Africa | Zambia | Ser450Leu | Ser315Thr | - | Met306Ile | _115del |
| strain_10 | MDR | L3.1.1 | Africa | Zambia | Ser450Leu | Ser315Thr | - | Met306Ile | Lys43Arg |
| strain_11 | MDR | L3.1.1 | Africa | Zambia | - | Ser315Thr | Met175Val | Met306Ile | Lys43Arg |
| strain_12 | MDR | L3.1.1 | Africa | Zambia | His445Tyr | Ser315Thr | - | multiple | - |
| strain_13 | MDR | L3.1.1 | Africa | Zambia | multiple | Ser315Thr | - | Met306Ile | - |
| SRR1162689 | Sensitive | L3.1.1 | Europe | Sweden | - | - | - | - | - |
| SRR1144826 | MDR | L3.1.1 | Europe | Sweden | - | - | - | - | - |
| SRR1144734 | MDR | L3.1.1 | Europe | Sweden | - | - | - | - | - |
| SRR1144803 | MDR | L3.1.1 | Europe | Sweden | - | - | - | - | multiple |
| SRR1162878 | MDR | L3.1.1 | Europe | Sweden | - | - | - | - | - |
| ERR3077930 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | Val128Gly | Gln497Arg | - |
| ERR3077934 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | _115del |
| ERR3077936 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077939 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | - | multiple | - |
| ERR3077940 | Pre-MDR | L3.1.1 | Africa | Tanzania | His445Arg | - | - | - | - |
| ERR3077948 | MDR | L3.1.1 | Africa | Tanzania | - | - | - | - | _115del |
| ERR3077949 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077950 | MDR | L3.1.1 | Africa | Tanzania | His445Asp | Ser315Thr | - | multiple | - |
| ERR3077952 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | multiple |
| ERR3077955 | MDR | L3.1.1 | Africa | Tanzania | multiple | Ser315Thr | multiple | Gln497Arg | - |
| ERR3077956 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | Val128Gly | multiple | - |
| ERR3077959 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077962 | Pre-MDR | L3.1.1 | Africa | Tanzania | Asp435Val | - | - | multiple | multiple |
| ERR3077963 | MDR | L3.1.1 | Africa | Tanzania | - | - | - | - | multiple |
| ERR3077964 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | Val128Gly | multiple | - |
| ERR3077965 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | Val128Gly | Gln497Arg | multiple |
| ERR3077970 | MDR | L3.1.1 | Africa | Tanzania | Leu452Pro | Ser315Thr | - | embA_c.-16C>T | - |
| ERR3077971 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | 3_2284488del | multiple | - |
| ERR3077972 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077974 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |

Table 9: List of global L3.1.1 (CAS1-Kili) strains and their mutations according to TB-profiler continues.....

| Accession No. | Drug resistance | Sublineage | Continent | Country | Drug resistance mutations | | | | |
|---------------|-----------------|------------|-----------|--------------|---------------------------|-----------|--------------|-----------|----------|
| | | | | | RIF | INH | PRZ | EMB | STM |
| ERR3077976 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077979 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077984 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077985 | MDR | L3.1.1 | Africa | Tanzania | multiple | Asn138Ser | - | multiple | - |
| ERR3077987 | Pre-MDR | L3.1.1 | Africa | Tanzania | - | Ser315Thr | - | - | - |
| ERR3077988 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077991 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077992 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | - | Met306Ile | - |
| ERR3077994 | MDR | L3.1.1 | Africa | Tanzania | multiple | Ser315Thr | _388del | Gln497Arg | multiple |
| ERR3077995 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3077999 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | 3_2284488del | Gly406Ala | - |
| ERR3078001 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | - |
| ERR3078002 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | multiple |
| ERR3078012 | Sensitive | L3.1.1 | Africa | Tanzania | - | - | - | - | multiple |
| ERR3078016 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | Val128Gly | Gln497Arg | _115del |
| ERR3078017 | MDR | L3.1.1 | Africa | Tanzania | Ser450Leu | Ser315Thr | Val128Gly | Gln497Arg | - |
| SRR1062878 | MDR | L3.1.1 | Africa | Uganda | His445Leu | Ser315Thr | - | Met306Val | _386del |
| SRR1062909 | Pre-MDR | L3.1.1 | Africa | Uganda | - | Ser315Thr | - | - | - |
| ERR040126 | MDR | L3.1.1 | Africa | Uganda | Ser450Leu | Ser315Thr | - | Met306Val | - |
| ERR040133 | Sensitive | L3.1.1 | Africa | Uganda | - | - | - | - | - |
| ERR2515846 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515691 | MDR | L3.1.1 | Africa | South_Africa | Ser450Leu | Ser315Asn | - | - | _107del |
| SRR833020 | Pre-MDR | L3.1.1 | Africa | South_Africa | - | - | - | - | _107del |
| SRR1011477 | MDR | L3.1.1 | Africa | South_Africa | Asp435Val | Ser315Thr | Trp68Cys | Met306Ile | _107del |
| SRR1165230 | MDR | L3.1.1 | Africa | South_Africa | multiple | Ser315Thr | Trp68Cys | Met306Ile | multiple |
| SRR1165270 | MDR | L3.1.1 | Africa | South_Africa | Ser450Leu | Ser315Thr | Trp68Cys | Met306Ile | _107del |
| SRR1165624 | Other | L3.1.1 | Africa | South_Africa | Asp435Val | Ser315Thr | Trp68Cys | Met306Ile | _107del |
| SRR1165649 | MDR | L3.1.1 | Africa | South_Africa | Ser450Leu | Ser315Thr | Trp68Cys | Met306Ile | multiple |
| SRR1165655 | MDR | L3.1.1 | Africa | South_Africa | Ser450Leu | Ser315Thr | Trp68Cys | Met306Ile | - |
| SRR1165657 | MDR | L3.1.1 | Africa | South_Africa | Asp435Val | Ser315Thr | Trp68Cys | Met306Ile | - |
| SRR1172744 | MDR | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| SRR1175029 | MDR | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR171128 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR171129 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR1034944 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515140 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515200 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515366 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515404 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515564 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515696 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515736 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |
| ERR2515846 | Sensitive | L3.1.1 | Africa | South_Africa | - | - | - | - | - |

CONCLUSION

MDR-TB is of great concern globally. It is a threat to TB control in Zambia. As country, Zambia is listed among the 30 countries with high TB, MDR/RR and TB/HIV burden countries in the world. Despite increasing reports of MDR-TB in routine surveillance, and an estimated increase in the number of MDR-TB cases among the new pulmonary TB patients, the information on transmission of MDR Mycobacterium tuberculosis strains is largely unknown. Therefore, this study elucidated the genetic diversity and transmission of MDR *M. tuberculosis* strains in Lusaka, Zambia.

In chapter 1, eighty-five MDR *M. tuberculosis* samples were evaluated using drug-resistance associated gene sequencing, spoligotyping, and 24-loci MIRU-VNTR. Multiplex PCR was applied for RD-Rio sub-lineage identification. The identified clades were LAM (48%), CAS (29%), T (14%), X (6%) and Harlem (2%). Many strains belonged to SIT 21/CAS1-Kili (29%) and SIT59/LAM11-ZWE (16%). Strains belonging to SITs 21/CAS1-Kili and 20/LAM1 formed the largest clonal complexes. Combined spoligotyping and 24 loci-MIRU-VNTR revealed a clustering rate of 63%. Additionally, ninety-five percent of LAM strains belonged to the RD-Rio sub-lineage. The cumulative Hunter Gaston discriminatory indices for 9, 15 and 24 MIRU-VNTR loci sets were 0.959, 0.965 and 0.973 respectively. The high clustering rate revealed by the study was suggestive of MDR-TB spread to be due to recent transmission than independent acquisition of MDR. This was attributed more to the clonal expansion of SIT21/CAS1-Kili, and SIT20/LAM1. Besides, based on the performance of the assessed MIRU-VNTR loci sets, the study proposed the use 9 and 15-loci MIRU-VNTR for epidemiological and phylogenetic studies on MDR-TB strains in this region, respectively.

While in chapter 2, twelve of the MDR CAS1-Kili isolates clustered by the traditional genotyping methods (spoligotyping and MIRU-VNTR) were further investigated for recent transmission using a high-resolution technique, WGS. Among the 12 CAS1-Kili strains, 92% (11/12) belonged to a cluster (≤ 12 SNPs) while 50% (6/12) were involved in recent transmission events, as they differed by ≤ 5 SNPs. All the 12 strains had KatG Ser315Thr (isoniazid resistance), EmbB Met306 substitutions (ethambutol resistance) and several kinds of *rpoB* mutations (rifampicin resistance). The study also revealed compensatory mutations including a novel deletion in *embA* regulatory region ($-35A > del$). Several strains shared the same combinations of drug-resistance-associated mutations indicating transmission of MDR strains. Moreover, the 12 Zambian strains belonged to the same clade as Tanzanian, Malawian and European strains. Therefore, the study emphasized the ongoing transmission of MDR

SIT21/CAS1-Kili strain in Lusaka, which is of public health concern and needs more evaluation. It also revealed the sequential acquisition of drug-resistance associated mutations which has both public health and clinical implications. Besides, the study suggested the origin of the CAS1-Kili strain to be Tanzania, then spread to Malawi before Zambia. This showed the importance of regional coordination in TB control. Therefore, diagnostic methods and local treatment protocols to rapidly identify these strains and isolate patients affected can help terminate the transmission chains.

ACKNOWLEDGMENTS

First and foremost, I would like to express my sincere gratitude to my supervisors, Professor Suzuki Yasuhiko and Professor Nakajima Chie for their unwavering support and guidance throughout my studies. I am also thankful to Professor Hideaki Higashi and Professor Norikazu Isoda for their opinions, recommendations, and guidance during the program. Many thanks to Professor Mukonka Victor for his timely advice and support he gave me during the course of the program. I would also like to extend my thanks to Yukari Fukushima and Mr. Mwale Kaemba for their technical support. Special thanks to Dr Solo Eddie for grating me permission to work on his samples. I also value the contributions of Assistant Professor Thapa Jeewan and all members of Bioresources. I am grateful to Japan International Cooperation Agency (JICA) for providing me with a scholarship to pursue this PhD program.

To my wife, Assah Namute, and my boys, Joseph Chizimu and Benjamin Chizimu, words can't express how much I am grateful to you, thank you. Thank you to my parents, brother, sisters and friends for their support and encouragements, which kept me going. My God, your grace has been so sufficient in my life. Who am I without you? Thank you for everything.

REFERENCES

- Agonafir M, Lemma E, Wolde-Meskel D, Goshu S, Santhanam A, Girmachew F, et al.** Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. *Int J Tuberc Lung Dis* 2010;**14**:1259–65.
- Alaridah N, Hallbäck ET, Tångrot J, Winqvist N, Sturegård E, Florén-Johansson K, et al.** Transmission dynamics study of tuberculosis isolates with whole genome sequencing in southern Sweden. *Sci Rep* 2019;**9**:1–9.
- Allix-Béguec C, Harmsen D, Weniger T, Supply P, Niemann S, Allix-Béguec C, et al.** Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of *Mycobacterium tuberculosis* complex isolates. *J Clin Microbiol* 2008;**46**:2692–9.
- De Almeida IN, Vasconcellos SEG, de Assis Figueredo LJ, Dantas NGT, Augusto CJ, Hadaad JPA, et al.** Frequency of the *Mycobacterium tuberculosis* RDRio genotype and its association with multidrug-resistant tuberculosis. *BMC Infect Dis* 2019;**19**:1–9.
- Alyamani EJ, Marcus SA, Ramirez-Busby SM, Hansen C, Rashid J, El-kholy A, et al.** Genomic analysis of the emergence of drug-resistant strains of *Mycobacterium tuberculosis* in the Middle East. *Sci Rep* 2019;**9**:1–12.
- Andersson DI.** The biological cost of mutational antibiotic resistance: any practical conclusions? *Curr Opin Microbiol* 2006;**9**:461–5.
- Asare P, Otchere ID, Bedeley E, Brites D, Loiseau C, Baddoo NA, et al.** Whole Genome Sequencing and Spatial Analysis Identifies Recent Tuberculosis Transmission Hotspots in Ghana. *Front Med* 2020;**7**:161.
- Bakula Z, Javed H, Pleń M, Jamil N, Tahir Z, Jagielski T.** Genetic diversity of multidrug-resistant *Mycobacterium tuberculosis* isolates in Punjab, Pakistan. *Infect Genet Evol* 2019;**72**:16–24.
- Bakula Z, Napiórkowska A, Bielecki J, Augustynowicz-Kopeć E, Zwolska Z, Jagielski T.** Mutations in the *embB* Gene and Their Association with Ethambutol Resistance in Multidrug-Resistant *Mycobacterium tuberculosis* Clinical Isolates from Poland. *Biomed Res Int* 2013;**2013**:167954.
- Balasubramanian V, Wiegshaus EH, Taylor BT, Smith DW.** Pathogenesis of tuberculosis: pathway to apical localization. *Tuber Lung Dis* 1994;**75**:168–78.
- Batut B, Hiltemann S, Bagnacani A, Baker D, Bhardwaj V, Blank C, et al.** Community-Driven Data Analysis Training for Biology. *Cell Syst* 2018;**6**:752--758.e1.
- Bhembe NL, Green E.** Molecular epidemiological study of multidrug-resistant tuberculosis isolated from sputum samples in Eastern Cape, South Africa. *Infect Genet Evol* 2020;**80**:104182.
- Bolger AM, Lohse M, Usadel B.** Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;**30**:2114–20.
- Boshoff HIM, Barry CE.** Tuberculosis — metabolism and respiration in the absence of growth. *Nat Rev Microbiol* 2005 31 2005;**3**:70–80.
- Brandis G, Wrande M, Liljas L, Hughes D.** Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. *Mol Microbiol* 2012;**85**:142–51.

Brynildsrud OB, Pepperell CS, Suffys P, Grandjean L, Monteserin J, Debech N, et al. Global expansion of *Mycobacterium tuberculosis* lineage 4 shaped by colonial migration and local adaptation. *Sci Adv* 2018;**4**:1–12.

Bwalya P, Yamaguchi T, Solo ES, Chizimu JY, Mbulo G, Nakajima C, et al. Characterization of Mutations Associated with Streptomycin Resistance in Multidrug-Resistant *Mycobacterium tuberculosis* in Zambia. *Antibiotics (Basel)* 2021;**10**:1169.

Casper C, Singh SP, Rave S, Daley CL, Schecter GS, Riley LW, et al. The transcontinental transmission of tuberculosis: A molecular epidemiological assessment. *Am J Public Health* 1996;**86**:551–3.

CDC. TB Risk Factors | Basic TB Facts | TB | CDC 2016.

Chihota VN, Müller B, Mlambo CK, Pillay M, Tait M, Streicher EM, et al. Population structure of multi- and extensively drug-resistant *Mycobacterium tuberculosis* strains in South Africa. *J Clin Microbiol* 2012;**50**:995–1002.

Chihota VN, Niehaus A, Streicher EM, Wang X, Sampson SL, Mason P, et al. Geospatial distribution of *Mycobacterium tuberculosis* genotypes in Africa. *PLoS One* 2018;**13**:e0200632.

Chizimu JY, Solo ES, Bwalya P, Kapalamula TF, Akapelwa ML, Lungu P, et al. Genetic Diversity and Transmission of Multidrug Resistant *Mycobacterium tuberculosis* strains in Lusaka, Zambia. *Int J Infect Dis* 2021;**114**: 142–150,.

CLC Genomics Workbench. CLC Genomics Workbench 20.0 (QIAGEN). Workbench 2013:1–70.

Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med* 2015;**7**:51.

Coll I Cerezo F. Bioinformatic analysis of *Mycobacterium tuberculosis* whole genome data. PhD thesis. London School of Hygiene & Tropical Medicine, London, UK, 2015.

Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-genome sequencing of rifampicin-resistant *Mycobacterium tuberculosis* strains identifies compensatory mutations in RNA polymerase genes. *Nat Genet* 2011;**44**:106–10.

Commissioner UNH, Grandi RF. UNHCR chief applauds Zambia's openness to refugees 2019.

Coscolla M. Biological and Epidemiological Consequences of MTBC Diversity. *Adv Exp Med Biol* 2017;**1019**:95–116.

Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* 2014;**43**:e15.

Daffé M, Draper P. The Envelope Layers of Mycobacteria with Reference to their Pathogenicity. *Adv Microb Physiol* 1997;**39**:131–203.

David S, Duarte EL, Leite CQF, Ribeiro J-NN, Maio J-NN, Paixão E, et al. Implication of the RDRio *Mycobacterium tuberculosis* sublineage in multidrug resistant tuberculosis in Portugal. *Infect Genet Evol* 2012;**12**:1362–7.

Demay C, Liens B, Burguière T, Hill V, Couvin D, Millet J, et al. SITVITWEB – A publicly available international multimarker database for studying *Mycobacterium tuberculosis* genetic diversity and molecular epidemiology. *Infect Genet Evol* 2012;**12**:755–66.

Disease Profiling Project. DNA Sequencing: Illumina Workflow Part-2 (DNA Tagmentation, Amplification, and Cleanup) 2018.

Easterbrook PJ, Gibson A, Murad S, Lamprecht D, Ives N, Ferguson A, et al. High rates of clustering of strains causing tuberculosis in Harare, Zimbabwe: A molecular epidemiological study. *J Clin Microbiol* 2004;**42**:4536–44.

Ernst JD. The immunological life cycle of tuberculosis. *Nat Rev Immunol* 2012;**12**:581–91.

Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* 2016;**32**:3047–8.

Feliciano CS, Namburete EI, Rodrigues Praça J, Peronni K, Dippenaar A, Warren RM, et al. Accuracy of whole genome sequencing versus phenotypic (MGIT) and commercial molecular tests for detection of drug-resistant *Mycobacterium tuberculosis* isolated from patients in Brazil and Mozambique. *Tuberculosis* 2018;**110**:59–67.

Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, et al. PhyResSE: a Web Tool Delineating *Mycobacterium tuberculosis* Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. *J Clin Microbiol* 2015;**53**:1908–14.

Gagneux S. Strain Variation in the *Mycobacterium tuberculosis* Complex : Its Role in Biology , Epidemiology and Control 2017; **1019**:319.

Gagneux S. Host-pathogen coevolution in human tuberculosis. *Philos Trans R Soc London Ser B, Biol Sci* 2012;**367**:850–9.

Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, et al. Variable host-pathogen compatibility in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 2006;**103**:2869–73.

Gillespie S. Tuberculosis: evolution in millennia and minutes. *Biochem Soc Trans* 2007;**35**:1317–20.

Gutierrez MC, Brisse S, Brosch R, Fabre M, Omaïs B, Marmiesse M, et al. Ancient Origin and Gene Mosaicism of the Progenitor of *Mycobacterium tuberculosis*. *PLOS Pathog* 2005;**1**:e5.

Hamblion EL, Le Menach A, Anderson LF, Lalor MK, Brown T, Abubakar I, et al. Recent TB transmission, clustering and predictors of large clusters in London, 2010–2012: Results from first 3-years of universal MIRU-VNTR strain typing. *Thorax* 2016;**71**:749–56.

Hazbón MH, Valle MB del, Guerrero MI, Varma-Basil M, Filliol I, Cavatore M, et al. Role of embB Codon 306 Mutations in *Mycobacterium tuberculosis* Revisited: a Novel Association with Broad Drug Resistance and IS6110 Clustering Rather than Ethambutol Resistance. *Antimicrob Agents Chemother* 2005;**49**:3794.

Heusden P van, Gladman S, Lose T. *M. tuberculosis* Variant Analysis (Galaxy Training Materials) 2021.

Hunter PR. Reproducibility and indices of discriminatory power of microbial typing methods. *J Clin Microbiol* 1990;**28**:1903–5.

Hunter PR, Gaston MA, Hunter PR, Gaston MA, Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems: An application of Simpson's index of diversity. *J Clin Microbiol* 1988;**26**:2465–6.

Kaiser G. The Prokaryotic cell- Bacteria. Microbiology. Community College of Baltimore County (Cantonsville): LibreTexts libraries 2019;782.

- Kalscheuer R, Palacios A, Anso I, Cifuentes J, Anguita J, Jacobs Jr WR, et al.** The *Mycobacterium tuberculosis* capsule: a cell structure with key implications in pathogenesis. *Biochem J* 2019;**476**:1995–2016.
- Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al.** Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *J Clin Microbiol* 1997;**35**:907–14.
- Kapata N, Chanda-Kapata P, Bates M, Mwaba P, Cobelens F, Grobusch MP, et al.** Multidrug-resistant TB in Zambia: Review of national data from 2000 to 2011. *Trop Med Int Heal* 2013;**18**:1386–91.
- Katale BZ, Mbelele PM, Lema NA, Campino S, Mshana SE, Rweyemamu MM, et al.** Whole genome sequencing of *Mycobacterium tuberculosis* isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania. *BMC Genomics* 2020;**21**:174.
- Kochi A, Varelzdis B, Styblo K.** Multidrug-resistant tuberculosis and its control. *Res Microbiol* 1993;**144**:104–10.
- Kurbatova E V., Kaminski DA, Erokhin V V., Volchenkov G V., Andreevskaya SN, Chernousova LN, et al.** Performance of Cepheid® Xpert MTB/RIF® and TB-Biochip® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis. *Eur J Clin Microbiol Infect Dis* 2013;**6**:735–43.
- Lacoma A, García-Sierra N, Prat C, Maldonado J, Ruiz-Manzano J, Haba L, et al.** GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in *Mycobacterium tuberculosis* strains and clinical samples. *J Clin Microbiol* 2012;**50**:30–6.
- Lalor M, Casali N, Walker T, Anderson L, Davidson J, Ratna N, et al.** The use of whole-genome sequencing in cluster investigation of an MDR-TB outbreak. *Eur Respir J* 2018;**51**:1702313.
- Lazzarini LCO, Huard RC, Boechat NL, Gomes HM, Oelemann MC, Kurepina N, et al.** Discovery of a novel *Mycobacterium tuberculosis* lineage that is a major cause of tuberculosis in Rio de Janeiro, Brazil. *J Clin Microbiol* 2007;**45**:3891–902.
- Lee ASG, Othman SNK, Ho YM, Wong SY.** Novel mutations within the embB gene in ethambutol-susceptible clinical isolates of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2004;**48**:4447–9.
- Leung ECC, Leung CC, Kam KM, Yew WW, Chang KC, Leung WM, et al.** Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city. *Eur Respir J* 2013;**41**:901–8.
- Li M, Chen R, Lin S, Lu Y, Liu H, Li G, et al.** Detecting Ethambutol Resistance in *Mycobacterium tuberculosis* Isolates in China: A Comparison Between Phenotypic Drug Susceptibility Testing Methods and DNA Sequencing of *embAB*. *Front Microbiol* 2020;**11**:781.
- Li Q jing, Jiao W wei, Yin Q qin, Li Y jia, Li J qiong, Xu F, et al.** Positive epistasis of major low-cost drug resistance mutations rpoB531-TTG and katG315-ACC depends on the phylogenetic background of *Mycobacterium tuberculosis* strains. *Int J Antimicrob Agents* 2017;**49**:757–62.
- Luo D, Chen Q, Xiong G, Peng Y, Liu T, Chen X, et al.** Prevalence and molecular characterization of multidrug-resistant *M. tuberculosis* in Jiangxi province, China. *Sci Rep* 2019;**9**:7315.
- Luo T, Yang C, Peng Y, Lu L, Sun G, Wu J, et al.** Whole-genome sequencing to detect

recent transmission of *Mycobacterium tuberculosis* in settings with a high burden of tuberculosis. *Tuberculosis (Edinb)* 2014;**94**:434–40.

Malama S, Muma J, Munyeme M, Mbulo G, Muwonge A, Shamputa IC, et al. Isolation and Molecular Characterization of *Mycobacterium tuberculosis* from Humans and Cattle in Namwala District, Zambia. *EcoHealth* 2014;**11**:564–70.

Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant *Mycobacterium tuberculosis* and a proposed gyrase numbering system. *J Antimicrob Chemother* 2012;**67**:819–31.

Mbugi E V., Katale BZ, Siame KK, Keyyu JD, Kendall SL, Dockrell HM, et al. Genetic diversity of *Mycobacterium tuberculosis* isolated from tuberculosis patients in the Serengeti ecosystem in Tanzania. *Tuberculosis* 2015;**95**:170–8.

Mbugi E V, Katale BZ, Streicher EM, Keyyu JD, Kendall SL, Dockrell HM, et al. Mapping of *Mycobacterium tuberculosis* Complex Genetic Diversity Profiles in Tanzania and Other African Countries. *PLoS One* 2016;**11**:e0154571.

Meier A, Sander P, Schaper KJ, Scholz M, Böttger EC. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1996;**40**:2452–54.

Metcalfe JZ, Kim EY, Lin S-YG, Cattamanchi A, Oh P, Flood J, et al. Determinants of Multidrug-Resistant Tuberculosis Clusters, California, USA, 2004–2007. *Emerg Infect Dis* 2010;**16**:1403–9.

Ministry of Health. Zambia National TB Strategic Plan 2017-2021 2017.

Mokrousov I, Vyazovaya A, Iwamoto T, Skiba Y, Pole I, Zhdanova S, et al. Latin-American-Mediterranean lineage of *Mycobacterium tuberculosis*: Human traces across pathogen's phylogeography. *Mol Phylogenet Evol* 2016;**99**:133–43.

Moström P, Gordon M, Sola C, Ridell M, Rastogi N. Methods used in the molecular epidemiology of tuberculosis. *Clin Microbiol Infect* 2002;**8**:694–704.

Mulenga C, Shamputa IC, Mwakazanga D, Kapata N, Portaels F, Rigouts L. Diversity of *Mycobacterium tuberculosis* genotypes circulating in Ndola, Zambia. *BMC Infect Dis* 2010;**10**:177.

Namburete EI, Dippenaar A, Conceição EC, Feliciano C, Nascimento MMP do, Peronni KC, et al. Phylogenomic assessment of drug-resistant *Mycobacterium tuberculosis* strains from Beira, Mozambique. *Tuberculosis* 2020;**121**:101905.

Napier G, Campino S, Merid Y, Abebe M, Woldeamanuel Y, Aseffa A, et al. Robust barcoding and identification of *Mycobacterium tuberculosis* lineages for epidemiological and clinical studies. *Genome Med* 2020 121 2020;**12**:1–10.

O'Neill MB, Shockey A, Zarley A, Aylward W, Eldholm V, Kitchen A, et al. Lineage specific histories of *Mycobacterium tuberculosis* dispersal in Africa and Eurasia. *Mol Ecol* 2019;**28**:3241–56.

Oudghiri A, Chaoui I, Elmzibri M. Molecular Epidemiology of Tuberculosis: A Review of Tools and Applications. *J Infect Dis Ther* 2018;**6**:1–7.

Oudghiri A, Momen G, Aainouss A, Laglaoui A, El Messaoudi MD, El Mzibri M, et al. Genotypic diversity of multi- and pre-extremely drug-resistant *Mycobacterium tuberculosis* isolates from Morocco. *PLoS One* 2021;**16**:e0253826.

- Palomino JC, Martin A.** Drug resistance mechanisms in *Mycobacterium tuberculosis*. *Antibiotics* 2014;**3**:317–40.
- Paradis E, Claude J SK.** APE: analyses of phylogenetics and evolution in R language. *Bioinformatics* 2004;**20**:289–90.
- Parsons LM, Salfinger M, Clobridge A, Dormandy J, Mirabello L, Polletta VL, et al.** Phenotypic and Molecular Characterization of *Mycobacterium tuberculosis* Isolates Resistant to both Isoniazid and Ethambutol. *Antimicrob Agents Chemother* 2005;**49**:2218.
- Perdigão J, Clemente S, Ramos J, Masakidi P, Machado D, Silva C, et al.** Genetic diversity, transmission dynamics and drug resistance of *Mycobacterium tuberculosis* in Angola. *Sci Rep* 2017;**7**:42814.
- Perdigão J, Silva C, Diniz J, Pereira C, Machado D, Ramos J, et al.** Clonal expansion across the seas as seen through CPLP-TB database: A joint effort in cataloguing *Mycobacterium tuberculosis* genetic diversity in Portuguese-speaking countries. *Infect Genet Evol* 2019;**72**:44–58.
- Phelan JE, O’Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, et al.** Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. *Genome Med* 2019;**11**:41.
- Qing S, Tong-yang X, Hai-can L, Xiu-qin Z, Zhi-guang L, Ya-nan L, et al.** Mutations within embCAB Are Associated with Variable Level of Ethambutol Resistance in *Mycobacterium tuberculosis* Isolates from China. *Antimicrob Agents Chemother* 2021;**62**:e01279–317.
- Ramaswamy S, Musser JM.** Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: 1998 update. *Tuber Lung Dis* 1998;**79**:3–29.
- Roetzer A, Diel R, Kohl TA, Rückert C, Nübel U, Blom J, et al.** Whole genome sequencing versus traditional genotyping for investigation of a *Mycobacterium tuberculosis* outbreak: a longitudinal molecular epidemiological study. *PLoS Med* 2013;**10**:e1001387.
- Safi H, Sayers B, Hazbón MH, Alland D.** Transfer of *embB* Codon 306 Mutations into Clinical *Mycobacterium tuberculosis* Strains Alters Susceptibility to Ethambutol, Isoniazid, and Rifampin. *Antimicrob Agents Chemother* 2008;**52**:2027-34.
- Sagonda T, Mupfumi L, Manzou R, Makamure B, Tshabalala M, Gwanzura L, et al.** Prevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe. *Tuberc Res Treat* 2014;**2014**:1–8.
- Said HM, Kock MM, Ismail NA, Mphahlele M, Baba K, Omar S V, et al.** Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant *Mycobacterium tuberculosis* isolates from the northern region of South Africa. *J Clin Microbiol* 2012;**50**:2857–62.
- Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, et al.** Characterization of *pncA* mutations in pyrazinamide-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1997;**41**:540–3.
- Seemann. T.** snippy: Rapid haploid variant calling and core genome alignment 2020.
- Shah Y, Maharjan B, Thapa J, Poudel A, Diab HM, Pandey BD, et al.** High diversity of multidrug-resistant *Mycobacterium tuberculosis* Central Asian Strain isolates in Nepal. *Int J Infect Dis* 2017;**63**:13–20.
- Shen X, Shen G, Wu J, Gui X, Li X, Mei J, et al.** Association between *embB* Codon 306

Mutations and Drug Resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2007;**51**:2618–20.

Shuaib YA, Khalil EAG, Wieler LH, Schaible UE, Bakheit MA, Mohamed-Noor SE, et al. *Mycobacterium tuberculosis* Complex Lineage 3 as Causative Agent of Pulmonary Tuberculosis, Eastern Sudan. *Emerg Infect Dis* 2020;**26**:427–36.

Silva C, Perdigão J, Jordão L, Portugal I. Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview. *Int J Antimicrob Agents* 2014;**44**:546–51.

Smith I. *Mycobacterium tuberculosis* Pathogenesis and Molecular Determinants of Virulence. *Clin Microbiol Rev* 2003;**16**:463–96.

Solo ES, Nakajima C, Kaile T, Bwalya P, Fukushima Y, Chila S, et al. Mutations of *rpoB*, *katG* and *inhA* genes in multidrug-resistant *Mycobacterium tuberculosis* isolates from Zambia. *J Glob Antimicrob Resist* 2020;**22**:302-7.

Solo ES, Suzuki Y, Kaile T, Bwalya P, Lungu P, Chizimu JY, et al. Characterization of *Mycobacterium tuberculosis* genotypes and their correlation to multidrug resistance in Lusaka, Zambia. *Int J Infect Dis* 2021;**102**:489–96.

Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, et al. Restricted structural gene polymorphism in the *Mycobacterium tuberculosis* complex indicates evolutionarily recent global dissemination. *Proc Natl Acad Sci U S A* 1997;**94**:9869–74.

Sun H, Zhang C, Xiang L, Pi R, Guo Z, Zheng C, et al. Characterization of mutations in streptomycin-resistant *Mycobacterium tuberculosis* isolates in Sichuan, China and the association between Beijing-lineage and dual-mutation in *gidB*. *Tuberculosis* 2016;**96**:102–6.

Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, et al. Proposal for Standardization of Optimized Mycobacterial Interspersed Repetitive Unit – Variable-Number Tandem Repeat Typing of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2006;**44**:4498–510.

Suzuki Y, Katsukawa C, Tamaru A, Abe C, Makino M, Mizuguchi Y, et al. Detection of kanamycin-resistant *Mycobacterium tuberculosis* by identifying mutations in the 16S rRNA gene. *J Clin Microbiol* 1998;**36**:1220–5.

Team Rs. RStudio: Integrated Development for R. RStudio, PBC, Boston, MA 2020.

Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, et al. The *emb* operon, a gene cluster of *Mycobacterium tuberculosis* involved in resistance to ethambutol. *Nat Med* 1997;**3**:567–70.

UNAIDS. Tuberculosis and Hiv Tb Is the Leading Cause of Death. vol. 54, p. 20. UNAIDS: Geneva, Switzerland: 2018.

Viegas SO, MacHado A, Groenheit R, Ghebremichael S, Pennhag A, Gudo PS, et al. Molecular diversity of *Mycobacterium tuberculosis* isolates from patients with pulmonary tuberculosis in Mozambique. *BMC Microbiol* 2010;**10**:195.

Walker TM, Ip CLC, Harrell RH, Evans JT, Kapatai G, Dediccoat MJ, et al. Whole-genome sequencing to delineate *Mycobacterium tuberculosis* outbreaks: a retrospective observational study. *Lancet Infect Dis* 2013;**13**:137–46.

Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, et al. A cluster of multidrug-resistant *Mycobacterium tuberculosis* among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. *Lancet Infect Dis* 2018;**18**:431–

40.

Weniger T, Krawczyk J, Supply P, Niemann S, Harmsen D. MIRU-VNTRplus: A web tool for polyphasic genotyping of *Mycobacterium tuberculosis* complex bacteria. vol. 38. 2010.

WHO. Global Tuberculosis Report 2021 2021a.

WHO. Global Tuberculosis Programme 2021b.

WHO. TB country, regional and global profiles 2021c.

WHO. TB profile 2021d.

WHO. WHO consolidated guidelines on tuberculosis Module 4: Treatment Drug-resistant tuberculosis treatment 2020.

WHO. ANNEX 2 Country profiles for 30 high-TB burden countries 2019a.

WHO. Global Tuberculosis Report 2019. 2019b.

WHO. ANNEX 2 Country profiles for 30 high-TB burden countries 2018.

WHO. Annex 2: Country profiles for 30 high-TB burden countries. Glob Tuberc Rep 2017 2017:1–61.

WHO. ANNEX 2 Country profiles for 30 high-TB burden countries 2016.

WHO 2019. Executive summary. 2019.

Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HIM, Barry CE. Mutations in *gidB* Confer Low-Level Streptomycin Resistance in *Mycobacterium tuberculosis*. Antimicrob Agents Chemother 2011;**55**:2515-22.

Xu G, Mao X, Wang J, Pan H. Clustering and recent transmission of *Mycobacterium tuberculosis* in a Chinese population. Infect Drug Resist 2018;**11**:323–30.

Xu Y, Cancino-Muñoz I, Torres-Puente M, Villamayor LM, Borrá R, Borrá s-Máñez M, et al. High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. PLoS Med. 2019;**16**:e1002961.

Yu G. Using ggtree to Visualize Data on Tree-Like Structures. Curr Protoc Bioinforma 2020;**69**:e96.

Yu G, Lam TT-Y, Zhu H, Guan Y. Two Methods for Mapping and Visualizing Associated Data on Phylogeny Using Ggtree. Mol Biol Evol 2018;**35**:3041–3.

Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods Ecol Evol 2017;**8**:28–36.